document incorporate reference portion abbvie inc proxy statement incorporate reference iii proxy statement file march item business separation abbott laboratories abbvie incorporate delaware april january abbvie independent company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott shareholder abbvie common stock begin trade regularway ticker symbol abbv new york stock exchange january overview abbvie global researchbase biopharmaceutical company abbvie develop market advanced therapy address world complex disease abbvie product focus treat condition chronic autoimmune disease include rheumatoid arthritis psoriasis crohn disease hepatitis c hcv human immunodeficiency virus hiv endometriosis thyroid disease parkinson disease complication associate chronic kidney disease cystic fibrosis health condition low testosterone abbvie pipeline promise new medicine include compound indication phase phase development important medical specialty immunology virologyliver disease oncology renal disease neurological disease woman health segment abbvie operate business segmentpharmaceutical product incorporate reference note entitle segment geographic area information note consolidated financial statement include item financial statement supplementary data sale information relate humira include item management discussion analysis financial condition result operationsresult operation product abbvie portfolio product include broad line therapy address world complex disease humira humira biologic therapy administer subcutaneous injection approve treat follow autoimmune disease united states canada mexico collectively north america european union condition principal market rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylose spondylitis north america european union crohn disease moderate severe north america european union plaque psoriasis moderate severe north america european union juvenile idiopathic arthritis north america european union ulcerative colitis moderate severe united states european union axial spondyloarthropathy united states european union pediatric crohn disease severe united states european union pediatric enthesitisrelate arthritis european union text report term abbvie refers abbvie inc delaware corporation abbvie inc consolidate subsidiary context require humira approve market include japan china brazil australia humira introduce market january humira account percent abbvie total net sale united states composition matter compound patent covering adalimumab sell trademark humira expect expire december equivalent european union patent expect expire majority european union country april abbvie continue dedicate substantial research development effort expand indication humira include field rheumatology gastroenterology pediatric crohn disease pediatric ulcerative colitis dermatology pediatric psoriasis hidradenitis suppurativa ophthalmology uveitis phase trial ongoing preparation regulatory application uveitis united states european union regulatory application hidradenitis suppurativa file united states european union abbvie continue work humira formulation delivery enhancement improve convenience overall patient experience hcv product viekira pak alloral shortcourse interferonfree therapy ribavirin treatment adult patient genotype chronic hepatitis c hcv include compensate cirrhosis viekira pak approve fda december europe abbvie hcv treatment market viekirax exviera approve use patient genotype genotype hcv european commission grant marketing authorization treatment january additional virology product abbvie additional virology product include kaletra norvir treatment hiv infection synagis prevention respiratory syncytial virus rsv infection high risk infant kaletra kaletra market aluvia emerge market prescription antihiv medicine contain protease inhibitor lopinavir ritonavir kaletra antihiv medication treatment maintain viral suppression people hiv norvir norvir ritonavir protease inhibitor indicate combination antiretroviral agent treatment hiv infection synagis synagis product market abbvie outside united states protect atrisk infant severe respiratory disease cause rsv metabolicshormone product metabolic hormone product target number condition include testosterone deficiency exocrine pancreatic insufficiency hypothyroidism product include androgel androgel testosterone replacement therapy male diagnose symptomatic low testosterone available strength percent percent creon creon pancreatic enzyme therapy exocrine pancreatic insufficiency condition occur patient cystic fibrosis chronic pancreatitis condition synthroid synthroid treatment hypothyroidism abbvie right sell androgel creon synthroid united states endocrinology product lupron market lucrin lupron depot product palliative treatment advance prostate cancer treatment endometriosis central precocious puberty preoperative treatment patient anemia cause uterine fibroid lupron approve daily subcutaneous injection onemonth threemonth fourmonth sixmonth intramuscular injection product abbvie product include follow duopa duodopa abbvie levodopacarbidopa intestinal gel treatment advanced parkinson disease market duopa united states duodopa outside united states anesthesia product sevoflurane sell trademark ultane sevorane anesthesia product abbvie sell worldwide human use dyslipidemia product abbvie dyslipidemia product tricor trilipix niaspan simcor advicor address range metabolic condition characterize high cholesterol andor high triglyceride zemplar zemplar product sell worldwide treatment secondary hyperparathyroidism associate stage chronic kidney disease ckd research development activity abbvie numerous compound clinical development include potential treatment complex lifethreatening disease abbvie ability discover develop new compound enhance company use integrate discovery development project team include chemist biologist physician pharmacologist work compound team research development process generally begin discovery research focus identification molecule desire effect give disease preclinical testing identify compound prove successful compound move clinical development generally include follow phase phase involve human test small number healthy volunteer patient assess safety tolerability potential dosing phase test drug efficacy disease relatively small group patient phase test drug demonstrate favorable result early phase significantly large patient population demonstrate efficacy safety base regulatory criterion clinical trial development phase provide datum require prepare submit new drug application nda biological license application bla submission regulatory approval fda similar government agency outside united states specific requirement eg scope clinical trial obtain regulatory approval vary different country geographic region research development process discovery new drug launch typically take year long research development new pharmaceutical product significant inherent uncertainty guarantee molecule receive regulatory approval require launch new drug indication addition development new product new formulation research development project include phase trial call post marketing study project clinical trial design conduct collect additional datum parameter benefit risk approve drug abbvie spend approximately billion billion billion research discover develop new product indication process improve exist product process expense consist primarily salary relate expense personnel license fee consulting payment contract research clinical drug supply manufacturing cost laboratory equipment facility clinical trial cost collaboration fee expense intellectual property protection regulatory exclusivity generally approval product entitle certain kind exclusivity applicable intellectual property regulatory regime abbvie seek patent protection available significant market andor country product development united states expiration date patent file june year filing date give patent relate pharmaceutical product obtain early development process give time need complete clinical trial development activity require regulatory approval length time product launch patent expiration significantly year drug price competition patent term restoration act commonly know hatchwaxman act permit patent holder seek patent extension commonly call patent term restoration patent product process make product regulate federal food drug cosmetic act length patent extension roughly base percent period time file investigational new drug application compound submission nda compound plus percent time period nda submission regulatory approval extension exceed year patent term remain regulatory approval exceed year pharmaceutical product entitle form legal regulatory exclusivity approval scope length requirement exclusivitie vary united states jurisdictions united states fda approve drug product contain active ingredient previously approve product typically entitle year nonpatent regulatory exclusivity product entitle year exclusivity approval base fda reliance new clinical study essential approval submit nda applicant nda applicant study product use child fda grant pediatric exclusivity extend day long exist exclusivity patent regulatory relate product product treat condition afflict relatively small population reasonable expectation research development cost recover fda designate pharmaceutical orphan drug grant seven year market exclusivity applicable law regulation dictate scope exclusivity product entitle approval particular country certain instance regulatory exclusivity protect product patent protection long available period time excess patent protection possible estimate product development total period scope exclusivity entitle regulatory approval obtain give length time require complete clinical development pharmaceutical product minimum maximum period exclusivity achieve individual case expect exceed year respectively estimate consider factor difficulty recreate manufacturing process particular product proprietary knowledge delay introduction generic follow product expiration applicable patent regulatory exclusivity period biologic entitle exclusivity biologic price competition innovation act pass march title vii patient protection affordable care act law provide pathway approval biosimilar follow expiration year exclusivity innovator biologic potential additional dayextension term conduct pediatric study biologic eligible orphan drug exclusivity discuss law include extensive process innovator biologic biosimilar manufacturer litigate patent infringement validity enforceability prior approval biosimilar european union create pathway approval biosimilar publish guideline approval certain biosimilar product complex nature biologic biosimilar product lead great regulatory scrutiny rigorous requirement approval followon biosimilar product small molecule generic pharmaceutical product european union reduce effect biosimilar sale innovator biologic compare sale erosion cause generic version small molecule pharmaceutical product abbvie own license right substantial number patent patent application abbvie license own patent portfolio thousand patent family include united states patent application andor issue patent contain nonunite state counterpart patent application patent application include patent expire period aggregate believe material importance operation abbvie business abbvie believe single patent license trademark relate group patent license trademark relate adalimumab sell trademark humira material relation company business united states composition matter compound patent cover adalimumab expect expire december equivalent european union patent expect expire majority european union country april addition follow patent license trademark significant relate lopinavirritonavir sell trademark kaletra aluvia relate ombitasvirparitaprevirritonavir dasabuvir sell trademark viekira pak viekirax exviera holkira pak relate testosterone sell trademark androgel united states composition matter patent cover lopinavir expect expire principal united states noncomposition matter patent cover lopinavirritonavir expect expire united states composition matter patent cover ombitasvir paritaprevir dasabuvir expect expire respectively principal united states non composition matter patent cover androgel percent expect expire include pediatric exclusivity agreement affect exclusivity discuss item management discussion analysis financial condition result operationsresult operation abbvie rely circumstance trade secret protect technology trade secret difficult protect abbvie seek protect technology product candidate confidentiality agreement employee consultant advisor contractor collaborator agreement breached abbvie adequate remedy breach addition abbvie trade secret know independently discover competitor extent abbvie employee consultant advisor contractor collaborator use intellectual property own work company dispute arise right relate result knowhow invention market sale distribution capability abbvie utilize combination dedicate commercial resource regional commercial resource distributorship market sell distribute product worldwide abbvie direct primary marketing effort secure prescription recommendation brand product physician key opinion leader health care provider manage care provider example health maintenance organization pharmacy benefit manager hospital state federal government agency example united states department veterans affairs united states department defense important customer abbvie market directly consumer united states company product sell pursuant prescription outside united states abbvie focus marketing effort key opinion leader payor physicians country regulatory body abbvie provide patient support program closely relate product abbvie product sell country abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse significant seasonal aspect abbvie business abbvie product sale affect end customer retail buying pattern fluctuation wholesaler inventory level factor united states abbvie distribute pharmaceutical product principally independent wholesale distributor sale directly pharmacie patient wholesale distributor mckesson corporation cardinal health inc amerisourcebergen corporation account substantially abbvie sale united states individual wholesaler account great percent abbvie gross sale united states outside united states sale directly customer distributor depend market serve wholesaler purchase product abbvie standard term condition sale certain product comarkete copromote company abbvie single customer customer lose material adverse effect company business material portion abbvie business subject renegotiation profit termination contract election government order generally fill current basis order backlog material abbvie business party agreement abbvie agreement party process development analytical service manufacture certain product abbvie procure certain product service limit number supplier case single supply source example filling package humira syrinx sell outside united states puerto rico perform single supplier different facility abbvie currently believe agreement material abbvie business substantially dependent abbvie maintain significant inventory humira syrinx reduce risk supply disruption syringefille packaging facility united states approve supply syrinx primary market outside united states puerto rico addition abbvie agreement party active pharmaceutical ingredient product manufacturing formulation development service fill finish packaging service transportation distribution logistic service certain product abbvie believe manufacture relate agreement material abbvie business substantially dependent individual agreement case abbvie maintain alternate supply relationship utilize undue disruption manufacturing process party fails perform contractual obligation abbvie maintain sufficient inventory product minimize impact supply disruption abbvie party certain collaboration arrangement discuss note acquisition collaboration arrangement note consolidated financial statement include item financial statement supplementary datum certain agreement abbott discuss item management discussion analysis financial condition result operationstransition abbott cost operate independent company source availability raw material abbvie purchase ordinary course business raw material supply essential operation numerous supplier world include united states addition certain medical device component necessary manufacture product provide unaffiliated party supplier abbvie experience recent significant availability problem supply shortage forecast sale environmental matter abbvie believe operation comply material respect applicable law regulation concern environmental protection regulation federal state environmental law impose stringent limitation emission discharge environment manufacturing operation abbvie capital operating expenditure pollution control approximately million million respectively capital operating expenditure pollution control estimate approximately million million respectively abbott identify potentially responsible party investigation andor remediation location united states include puerto rico comprehensive environmental response compensation liability act commonly know superfund location transfer abbvie connection separation distribution abbvie party investigation remediations abbott engage remediation site transfer abbvie connection separation distribution cooperation environmental protection agency similar agency feasible predict certainty final cost relate investigation remediation activity abbvie believe cost expenditure maintain compliance applicable law regulation concern environmental protection material adverse effect company financial position cash flow result operation competition market abbvie product highly competitive abbvie compete researchbase pharmaceutical biotechnology company discover manufacture market sell proprietary pharmaceutical product biologic example humira compete number antitnf product approve number disease state abbvie virology product compete protease inhibitor antihiv treatment search technological innovation pharmaceutical product significant aspect competition introduction new product competitor change medical practice procedure result product obsolescence price competitive factor addition substitution generic pharmaceutical product brand pharmaceutical product create competitive pressure abbvie product patent protection biosimilar competition abbvie biologic product affect approval followon biologic know biosimilar biologic add major therapeutic option treatment disease include therapy unavailable inadequate advent biologic raise complex regulatory issue significant pharmacoeconomic concern cost develop produce biologic therapy typically dramatically high conventional small molecule medication expensive biologic medication ongoing treatment chronic disease rheumatoid arthritis inflammatory bowel disease treatment previously untreatable cancer significant investment biologics infrastructure manufacture necessary produce biologic product significant investment market distribution sale organization activity limit number biosimilar competitor united states fda regulate biologics federal food drug cosmetic act public health service act implement regulation enactment federal health care reform legislation march provide pathway approval biosimilar public health service act approval process science biosimilar complex approval process science generic followon version small molecule product add complexity step need ensure safety efficacy biosimilar highly similar original biologic humira ultimate approval fda dependent factor include show biosimilar highly similar original product clinically meaningful difference original product term safety purity potency vitro characterization type datum ordinarily require application similarity include analytical datum study demonstrate chemical similarity animal study include toxicity study clinical study law require biosimilar indication approve original biologic manufacturing facility meet standard necessary assure biosimilar safe pure potent furthermore new law provide biosimilar product deem interchangeable consider fda substitutable original biologic product intervention health care provider prescribe original biologic product prove biosimilar product interchangeable applicant demonstrate product expect produce clinical result original biologic product give patient product administer patient safety risk potential diminished efficacy alternating switching use interchangeable biosimilar biologic product original biologic product great risk original biologic product switch new law beginning interpret implement fda result ultimate impact implementation mean likely subject substantial uncertainty year come european union pathway approval biosimilar exist product come market date mixed impact market share incumbent product significant variation product competitive product number competitive biologic brand product approve humira introduce gain modest share worldwide market abbvie continue face competitive pressure biologic orally administer product regulationdiscovery clinical development united states secure approval market new pharmaceutical product united states require substantial effort financial resource take year complete applicant complete preclinical test obtain fda approval commence clinical trial clinical trial intend establish safety efficacy pharmaceutical product typically conduct sequential phase phase overlap combine require clinical testing successful result submit fda form nda bla request approval market product indication fda review nda bla determine product safe effective intended use manufacturing compliant current good manufacturing practice cgmp nda bla receive approval applicant comply postapproval requirement example holder approval report adverse reaction provide update safety efficacy information comply requirement concern advertise promotional labeling quality control manufacturing procedure continue conform cgmp approval fda periodically inspect manufacture facility assess compliance cgmp impose extensive procedural substantive record keeping requirement addition condition approval fda require postmarkete testing surveillance assess monitor product safety efficacy commercialization postapproval regulatory obligation cost comply obligation expand future outside united states abbvie subject similar regulation outside united states abbvie obtain approval clinical trial application product applicable regulatory authority commence clinical trial marketing product approval requirement process vary time require obtain approval long shorter require fda approval example abbvie submit marketing authorization european union centralize decentralize procedure centralize procedure mandatory approval biotechnology product pharmaceutical product provide single marketing authorization valid european union member state centralized procedure single marketing authorization application submit european medicine agency agency evaluate application make recommendation european commission make final determination approve application decentralize procedure provide mutual recognition national approval decision available product subject centralized procedure japan application approval new product pharmaceutical medical device agency pmda bridge study demonstrate foreign clinical datum apply japanese patient require complete comprehensive review pmda report ministry health labour welfare approve deny application regulatory process emerge market continue evolve emerge market include asia generally require regulatory approval obtain large develop market united states country begin complete regulatory review process country require local clinical study conduct order obtain regulatory approval country requirement govern conduct clinical trial product licensing vary addition postapproval regulatory obligation adverse event report cgmp compliance generally apply vary country example marketing authorization grant european union periodic safety report submit pharmacovigilance measure implement regulationcommercialization distribution manufacturing manufacture marketing sale promotion distribution abbvie product subject comprehensive government regulation government regulation national regional federal state local agency united states country address matter inspection control research laboratory procedure clinical investigation product approval manufacturing labeling packaging marketing promotion pricing reimbursement sampling distribution quality control postmarkete surveillance record keeping storage disposal practice abbvie operation affect trade regulation country limit import raw material finish product law regulation seek prevent corruption bribery marketplace include united states foreign corrupt practice act united kingdom bribery act provide guidance corporate interaction government official require safeguard protection personal datum addition abbvie subject law regulation pertain health care fraud abuse include state federal antikickback false claim law united states prescription drug manufacturer abbvie subject taxis application product user establishment fee compliance law regulation costly materially affect abbvie business effect health care regulation substantially increase time difficulty cost incur obtain maintain approval market newly develop exist product abbvie expect compliance regulation continue require significant technical expertise capital investment ensure compliance failure comply delay release new product result regulatory enforcement action seizure recall product suspension revocation authority necessary product production sale civil criminal sanction include fine penalty addition regulatory initiative abbvie business affect ongoing study utilization safety efficacy outcomes health care product component regularly conduct industry participant government agency study question utilization safety efficacy previously market product case study result future result discontinuance limitation marketing product domestically worldwide rise claim damage person believe injure result use access human health care product continue subject investigation action governmental agency legislative body private organization united states country major focus cost containment effort reduce health care cost private sector notably health care payor provider institute cost reduction containment measure abbvie expect insurer provider continue attempt reduce cost health care product outside united states country control price health care product directly indirectly reimbursement payment pricing coverage limitation compulsory license budgetary pressure united states country heighten scope severity pricing pressure abbvie product foreseeable future united states specifically federal law require pharmaceutical manufacturer pay certain statutorilyprescribe rebate state medicaid programs prescription drug reimburse state medicaid plan effort state seek additional rebate affect abbvie business similarly veteran health care act prerequisite participation medicaid federal health care program require manufacturer extend additional discount pharmaceutical product federal agency include united states department veterans affairs department defense public health service entity institution addition recent legislative change require similarly discount price offer tricare program beneficiary veterans health care act establish b drug discount program require pharmaceutical manufacturer provide product reduce price designate health care entity facilities united states states generic substitution legislation require permit dispense pharmacist substitute different manufacturer generic version pharmaceutical product prescribe addition federal government follows diagnosisrelate group drg payment system certain institutional service provide medicare medicaid implement prospective payment system pps service deliver hospital outpatient nursing home home health setting drg pps entitle health care facility fix reimbursement base diagnosis andor procedure actual cost incur patient treatment increase incentive facility limit control expenditure health care product medicare reimburse b drug base average sale price plus certain percentage account physician administration cost recently reduce hospital outpatient set end stage renal disease treatment cover bundle payment likewise create incentive provider demand low pharmaceutical price medicare enter contract private plan negotiate price patientadministere medicine deliver march congress enact patient protection affordable care act health care education reconciliation act affordable care act affordable care act abbvie pay fee relate pharmaceutical sale government program abbvie begin provide discount percent brand prescription drug sell patient fall medicare coverage gap donut hole affordable care act include provision know physician payment sunshine act require manufacturers drug biologics cover medicare medicaid start record transfer value physician teach hospital report datum beginning center medicare medicaid services subsequent public disclosure similar reporting requirement enact state level united states increase number country worldwide adopt consider similar law require disclosure interaction health care professional failure report appropriate datum result civil criminal fine andor penalty abbvie expect debate continue government level worldwide marketing availability method delivery payment health care product service abbvie believe future legislation regulation market serve affect access health care product service increase rebate reduce price rate price increase health care product service change health care delivery system create new fee obligation pharmaceutical industry require additional reporting disclosure possible predict extent abbvie health care industry general affect matter discuss abbvie subject corporate integrity agreement cia enter abbott require enhancement abbvie compliance program contain report obligation include disclosure financial payment doctor abbvie fail comply cia office inspector general united states department health human service impose monetary penalty exclude abbvie federal health care program include medicare medicaid european union european union adopt directive legislation govern label advertising distribution supply pharmacovigilance marketing pharmaceutical product legislation provide mandatory standard european union permit member states supplement standard additional regulation european government regulate pharmaceutical product price control national health care system fund large cost product consumer result patient unlikely use pharmaceutical product reimburse government european country government regulate price new product launch subsequent launch direct price control reference pricing recent year country impose new additional cost containment measure pharmaceutical product difference national pricing regime create price differential european union lead significant parallel trade pharmaceutical product government promote generic substitution mandate permit pharmacist substitute different manufacturer generic version pharmaceutical product prescribe permit mandate health care professional prescribe generic version certain circumstance addition government use reimbursement list limit pharmaceutical product eligible reimbursement national health care systems japan japan national health insurance system maintain drug price list specify pharmaceutical product eligible reimbursement ministry health labour welfare set price product list government generally introduce price cut round year mandate price decrease specific product new product judge innovative useful indicate pediatric use target orphan small population disease eligible pricing premium government promote use generic available emerge market emerge market step reduce pharmaceutical product price case direct price control promotion generic alternative brand pharmaceutical abbvie market product worldwide certain product local nature variation product line meet local regulatory requirement certain additional risk inherent conduct business outside united states include price currency exchange control change currency exchange rate limitation participation local enterprise expropriation nationalization governmental action employee abbvie employ approximately person january outside united states abbvie employee represent union work council abbvie believe good relation employee internet information copy abbvie annual report quarterly report form q current report form k amendment report file furnish pursuant section security exchange act available free charge abbvie investor relation website wwwabbvieinvestorcom soon reasonably practicable abbvie electronically file material furnish securities exchange commission abbvie corporate governance guideline outline directorship qualification code business conduct charters abbvie audit committee compensation committee nomination governance committee public policy committee available abbvie investor relation website wwwabbvieinvestorcom item risk factor carefully consider follow risk information evaluate abbvie abbvie common stock follow risk materially adversely affect abbvie result operation financial condition cash flow risk factor generally separate group risk relate abbvie business risk relate abbvie separation abbott risk relate abbvie common stock base information currently know abbvie believe follow information identify significant risk factor affect category risk risk uncertainty abbvie face limit set forth risk factor describe order importance probability occurrence additional risk uncertainty presently know abbvie abbvie currently believe immaterial adversely affect business addition past financial performance reliable indicator future performance historical trend anticipate result trend future period follow risk uncertainty develop actual event event material adverse effect abbvie business result operation financial condition cash flow case trading price abbvie common stock decline risk relate abbvie business expiration loss patent protection license adversely affect abbvie future revenue operate earning abbvie rely patent trademark intellectual property protection discovery development manufacturing sale product particular patent protection aggregate important abbvie marketing pharmaceutical product united states major market outside united states patent cover abbvie product normally provide market exclusivity important profitability abbvie product patent certain product expire abbvie face competition lower price generic product expiration loss patent protection product typically follow promptly substitute significantly reduce sale product short time abbvie competitive position compromise generic material adverse effect abbvie business result operation addition proposal emerge time time legislation encourage early rapid approval generic drug proposal enact law increase impact generic competition abbvie principal patent trademark describe great detail item businessintellectual property protection regulatory exclusivity item management discussion analysis financial condition result operationsresult operation litigation patent describe item legal proceeding united states composition matter patent humira abbvie large selling product worldwide net sale approximately billion expect expire december equivalent european union patent expect expire majority european union country april humira biologic biologic readily substitute uncertain impact loss patent protection sale humira abbvie major product lose patent protection early expect adversely affect abbvie future revenue operate earning party government authority challenge seek invalidate circumvent abbvie patent patent application example manufacturer generic pharmaceutical product file continue file abbreviate new drug application fda seek market generic form abbvie product prior expiration relevant patent own license abbvie assert patent invalid unenforceable andor infringe challenge abbvie intellectual property come business government challenge intellectual property right example court decision potential legislation relate patent legislation biosimilar regulatory initiative result erosion intellectual property protection addition certain government outside united states indicate compulsory license patent seek domestic policy basis national emergency hivaid trigger compulsory license diminish eliminate sale profit jurisdiction negatively affect abbvie result operation abbvie normally respond challenge vigorously defend patent include file patent infringement lawsuit patent litigation challenge abbvie patent costly unpredictable deprive abbvie market exclusivity patent product extent abbvie intellectual property successfully challenge circumvent extent intellectual property allow abbvie compete effectively abbvie business suffer extent country enforce abbvie intellectual property right require compulsory licensing abbvie intellectual property abbvie future revenue operating income reduce party intellectual property prevent abbvie selling product material adverse effect abbvie future profitability financial condition party claim abbvie product infringe intellectual property resolve intellectual property infringement claim costly time consuming require abbvie enter license agreement abbvie guarantee able obtain license agreement commercially reasonable term successful claim patent intellectual property infringement subject abbvie significant damage injunction prevent manufacture sale use affect abbvie product product event material adverse effect abbvie profitability financial condition significant event adversely affect humira revenue material negative impact abbvie result operation cash flow humira account approximately percent abbvie total net sale significant event adversely affect humira revenue material adverse impact abbvie result operation cash flow event include loss patent protection humira approval biosimilar humira discovery previously unknown effect impair efficacy increase competition introduction new effective expensive treatment discontinuation removal market humira reason abbvie research development effort succeed develop marketing commercially successful product technology cause revenue profitability decline remain competitive abbvie continue launch new product new indication andor brand extension exist product launch generate revenue sufficient cover substantial research development cost replace sale profitable product lose displace compete product therapy failure material adverse effect abbvie revenue profitability accordingly abbvie commit substantial effort fund resource research development ongoing substantial expenditure assurance effort commercially successful high rate failure biopharmaceutical industry inherent research development new product failure occur point research development process include significant fund invest product appear promise development fail reach market numerous reason include failure demonstrate effectiveness safety concern superior safety efficacy compete therapy failure achieve positive clinical preclinical outcome current standard care inability obtain necessary regulatory approval delay approval new product new indication limited scope approve use excessive cost manufacture failure obtain maintain intellectual property right infringement intellectual property right decision research study early development process pharmaceutical product candidate affect marketing strategy candidate receive approval detailed study demonstrate additional benefit help marketing consume time resource delay submit pharmaceutical product candidate approval abbvie guarantee proper balance speed testing respect pharmaceutical product candidate decision area adversely affect abbvie future result operation abbvie successfully develop market new product enhancement exist product quickly render obsolete change clinical preference change industry standard competitor innovation abbvie innovation accept quickly marketplace exist clinical practice uncertainty thirdparty reimbursement abbvie state certainty product development launch able develop license acquire compound product product commercially successful failure launch successful new product new indication exist product cause abbvie product obsolete cause abbvie revenue operate result suffer portion abbvie nearterm pharmaceutical pipeline rely collaboration party adversely affect development sale product abbvie depend alliance pharmaceutical biotechnology company portion product nearterm pharmaceutical pipeline example abbvie collaborate biogen idec develop treatment relapse remit form multiple sclerosis collaborate roche holding ag discover develop commercialize nextgeneration bcl inhibitor abt patient relapsedrefractory chronic lymphocytic leukemia failure party meet contractual regulatory obligation abbvie disruption relationship abbvie party adverse effect abbvie pharmaceutical pipeline business addition abbvie collaborative relationship research development extend year rise dispute relative right obligation revenue abbvie collaboration partner include ownership intellectual property associate right obligation result loss intellectual property right protection delay development sale potential pharmaceutical product lead lengthy expensive litigation arbitration biologic carry unique risk uncertainty negative impact future result operation successful discovery development manufacturing sale biologic long expensive uncertain process unique risk uncertainty biologic example access supply necessary biological material cell line limit governmental regulation restrict access regulate transport use material addition development manufacturing sale biologic subject regulation complex extensive regulation applicable pharmaceutical product manufacture biologic especially large quantity complex require use innovative technology manufacturing require facility specifically design validate purpose sophisticated quality assurance quality control procedure biologic frequently costly manufacture production input derive live animal plant material biologic synthetically failure successfully discover develop manufacture sell biologicsincluding humira adversely impact abbvie business result operation abbvie biologic product subject competition biosimilar biologics price competition innovation act pass march title vii patient protection affordable care act law create framework approval biosimilar united states allow competitor reference datum biologic product approve europe european commission grant marketing authorization biosimilar pursuant set general product classspecific guideline biosimilar approval issue past year addition company develop biosimilar country compete abbvie biologic product competitor able obtain marketing approval biosimilar reference abbvie biologic product abbvie product subject competition biosimilar attendant competitive pressure consequence expiration successful challenge abbvie applicable patent right trigger competition product assume relevant exclusivity period expire result abbvie face litigation respect validity andor scope patent relate biologic product new product technological advance abbvie competitor negatively affect abbvie result operation abbvie compete researchbase pharmaceutical biotechnology company discover manufacture market sell proprietary pharmaceutical product biologic example humira compete number antitnf product approve number disease states abbvie virology product compete protease inhibitor antihiv treatment competitor introduce new product develop technological advance compete abbvie product therapeutic area immunology virologyliver disease renal disease dyslipidemia neuroscience abbvie predict certainty timing impact introduction competitor new product technological advance compete product safer effective effectively market sell low price superior performance feature abbvie product negatively impact abbvie business result operation manufacture abbvie product highly exact complex process abbvie supplier encounter problem manufacture abbvie product abbvie business suffer manufacture abbvie product highly exact complex process strict regulatory requirement problem arise manufacturing variety reason include equipment malfunction failure follow specific protocol procedure problem raw material delay relate construction new facility expansion exist facility include intended support future demand abbvie product change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation inhibit continuous supply manmade natural disaster environmental factor problem arise production batch product batch product discard abbvie experience product shortage incur add expense thing lead increase cost lose revenue damage customer relation time expense spend investigate cause depend cause similar loss respect batch product problem discover product release market recall product liability cost incur abbvie use number product pharmaceutical biologic manufacturing process source single supplier interruption supply product adversely affect abbvie business result operation abbvie use number product pharmaceutical biologic manufacturing process source single supplier failure single source supplier fulfill contractual obligation timely manner result regulatory noncompliance physical disruption manufacturing site impair abbvie ability deliver product customer timely competitive basis adversely affect abbvie business result operation find alternative supplier significant time involve significant expense nature product need obtain regulatory approval abbvie guarantee able reach agreement alternative provider regulatory authority approve abbvie use alternative abbvie carry business interruption insurance provide degree protection case failure singlesource supplier significant safety efficacy issue arise abbvie product material adverse effect abbvie revenue financial condition pharmaceutical product receive regulatory approval base datum obtain control clinical trial limit duration follow regulatory approval product long period time patient investigator conduct additional extensive study new safety efficacy issue report new scientific information available include result postmarkete phase trial government change standard safety efficacy labeling abbvie require amend condition use product example abbvie voluntarily provide require provide update information product label narrow approve indication reduce product market acceptance safety efficacy issue abbvie product arise sale product halt abbvie regulatory authority safety efficacy issue affect supplier competitor product reduce market acceptance abbvie product new data abbvie product product similar product negatively impact demand abbvie product real perceive safety issue uncertainty efficacy case result product withdrawal furthermore new data information include information product misuse lead government agency professional society practice management group organization involve disease publish guideline recommendation relate use abbvie product use related therapy place restriction sale guideline recommendation lead low sale abbvie product abbvie subject product liability claim lawsuit adversely affect business result operation ordinary course business abbvie subject product liability claim lawsuit allege abbvie product product company promote result result unsafe condition injury patient product liability claim lawsuit safety alert product recall regardless ultimate outcome material adverse effect abbvie business reputation ability attract retain customer consequence include additional cost decrease market share product question low income exposure claim product liability loss selfinsure product liability claim material adverse effect abbvie business result operation abbvie subject costcontainment effort pricing pressure cause reduction future revenue operate earning change term rebate chargeback programs common pharmaceutical industry material adverse effect abbvie operation costcontainment effort government private organization describe great detail item businessregulationcommercialization distribution manufacturing extent cost containment effort offset great demand increase patient access health care factor abbvie future revenue operate earning reduce united states european union country abbvie business experience downward pressure product pricing pressure increase future united states practice manage care group institutional governmental purchaser united states federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act contribute pricing pressure recently enact change health care system united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result additional pricing pressure numerous major market worldwide government play significant role fund health care service determine pricing reimbursement pharmaceutical product consequently market abbvie subject government decisionmake budgetary action respect product particular european country ongoing governmentmandate price reduction pharmaceutical product abbvie anticipate continue pricing pressure europe difference country pricing regulation lead thirdparty crossborder trading abbvie product result reduction future revenue operate earning rebate relate government program feeforservice medicaid medicaid manage care program arise law regulation abbvie predict additional government initiative contain health care cost factor lead new modify regulatory requirement include high incremental rebate discount rebate discount program arise contractual agreement private payer factor include market factor ability private payer control patient access product provide payer leverage negotiate high additional rebate discount material adverse effect abbvie operation abbvie subject numerous governmental regulation costly comply regulation develop compliant product process abbvie product subject rigorous regulation numerous international supranational federal state authority describe item business regulationdiscovery clinical development process obtain regulatory approval market pharmaceutical product costly time consume approval grant future product additional indication use exist product timely basis delay receipt failure obtain approval future product new indication use result delay realization product revenue reduction revenue substantial additional cost addition abbvie guarantee remain compliant applicable regulatory requirement approval obtain product requirement include thing regulation manufacturing practice product label advertising postmarkete reporting include adverse event report field alert manufacturing quality concern abbvie incur expense spend time effort ensure compliance complex regulation possible regulatory action result substantial modification abbvie business practice operation refund recall seizures abbvie product total partial shutdown production abbvie supplier facility abbvie supplier remedy allege violation inability obtain future approval withdrawal suspension current product market event disrupt abbvie business material adverse effect business result operation law regulation affect government benefit program impose new obligation abbvie require change business practice restrict operation future health care industry subject federal state international law regulation pertain government benefit program reimbursement rebate price reporting regulation health care fraud abuse united states law include antikickback false claim law medicaid rebate statute veterans health care act individual state law relate pricing sale marketing practice violation law punishable criminal andor civil sanction include instance substantial fine imprisonment exclusion participation federal state health care program include medicare medicaid veterans administration health program law regulation broad scope subject change evolving interpretation require abbvie incur substantial cost associate compliance alter sale marketing practice addition violation law allegation violation disrupt abbvie business result material adverse effect business result operation abbvie subject increase monetary penalty andor sanction include exclusion federal health care program fail comply term resolution department justice investigation sale marketing activity depakote abbott settle united states federal state investigation sale marketing activity depakote plead guilty misdemeanor violation food drug cosmetic act agree pay approximately million criminal fine forfeiture approximately million resolve civil claim plea agreement abbott submit term probation initially set year shorten year separation abbott abbvie obligation plea agreement transfer fully bind abbvie condition probation include certain reporting requirement maintenance certain compliance measure certification abbvie ceo board director condition abbvie violate term probation face additional monetary sanction remedy court deem appropriate october court accept guilty plea impose agreedupon sentence addition abbott enter fiveyear cia office inspector general united states department health human service oig effective date cia october obligation cia transfer fully bind abbvie cia require enhancement abbvie compliance program fulfillment report monitoring obligation management certification resolution abbvie board director requirement compliance requirement settlement impose additional cost burden abbvie include form employee training party review compliance monitoring report obligation management attention abbvie fail comply cia oig impose monetary penalty exclude abbvie federal health care program include medicare medicaid abbvie abbott subject party claim shareholder lawsuit connection settlement abbvie require indemnify portion abbott cost international nature abbvie business subject additional business risk cause revenue profitability decline abbvie business subject risk associate business internationally include emerge market sale outside united states approximately percent abbvie total net sale risk associate abbvie operation outside united state include fluctuation currency exchange rate change medical reimbursement policy program multiple legal regulatory requirement subject change restrict abbvie ability manufacture market sell product differ local product preference product requirement trade protection measure import export licensing requirement difficulty establish staffing manage operation differ labor regulation potentially negative consequence change interpretation tax law political economic instability include sovereign debt issue price currency exchange control limitation participation local enterprise expropriation nationalization governmental action inflation recession fluctuation interest rate potential deterioration economic position credit quality certain nonus country include europe latin america potential penalty adverse consequence violation anticorruption antibribery similar law regulation include united states foreign corrupt practice act united kingdom bribery act event contemplate risk individually aggregate material adverse effect abbvie revenue profitability abbvie acquire business license right technology product form alliance dispose asset cause incur significant expense negatively affect profitability abbvie pursue acquisition technology licensing arrangement strategic alliance dispose asset business strategy abbvie complete transaction timely manner costeffective basis realize expect benefit abbvie successful making acquisition product technology acquire successful require significantly great resource investment originally anticipate abbvie able integrate acquisition successfully exist business incur assume significant debt unknown contingent liability abbvie experience negative effect report result operation acquisition dispositionrelate charge amortization expense relate intangible charge impairment longterm asset effect cause deterioration abbvie credit rating result increase borrowing cost interest expense additionally change abbvie structure operation revenue cost efficiency result major transaction acquisition divestiture merger alliance restructuring strategic initiative result great expect cost long expect complete encounter difficulty include need regulatory approval appropriate abbvie dependent wholesale distributor distribution product united states accordingly result operation adversely affect encounter financial difficulty wholesale distributorsamerisourcebergen corporation cardinal health inc mckesson corporationaccounte substantially abbvie sale united states significant wholesale distributor encounter financial difficulty distributor decrease business abbvie abbvie unable collect amount distributor owe timely basis negatively impact abbvie business result operation abbvie debt obligation adversely affect business ability meet obligation debt abbvie incur intend incur important consequence abbvie investor consequence include thing require portion abbvie cash flow operation interest payment debt reduce cash flow available fund capital expenditure corporate purpose grow abbvie business extent abbvie incur additional indebtedness risk increase addition abbvie cash flow operation sufficient repay outstanding debt abbvie able borrow money sell asset raise fund acceptable term refinance debt abbvie need additional financing future meet capital need opportunistic acquisition financing available favorable term abbvie need seek additional financing general corporate purpose example need increase investment research development activity need fund acquisition abbvie unable obtain desire additional financing term favorable abbvie lose investment grade credit rating adequate fund available acceptable term abbvie unable fund expansion successfully develop enhance product respond competitive pressure negatively affect abbvie business abbvie raise additional fund issue debt enter credit facility subject limitation operation restrictive covenant failure comply covenant adversely affect abbvie business abbvie depend information technology failure system adversely affect abbvie business abbvie rely sophisticated information technology system operate business system potentially vulnerable malicious intrusion random attack loss datum privacy breakdown abbvie invest protection datum information technology monitor system ongoing basis assurance effort prevent breakdown breaches abbvie information technology system adversely affect abbvie business factor material adverse effect abbvie profitability financial condition factor affect abbvie profitability financial condition include change interpretation law regulation include change accounting standard taxation requirement product marketing application standard environmental law difference fair value measurement asset liability actual value particularly pension postemployment benefit stockbase compensation intangible goodwill contingent liability litigation absence record record minimum compare actual change rate inflation include cost raw material commodity supply interest rate market value abbvie equity investment performance investment hold employee benefit trust change creditworthiness counterpartie transact business provide service abbvie employee benefit trust change business economic political condition include war political instability terrorist attack threat future terrorist activity relate military action natural disaster cost availability insurance forego event labor dispute strike slowdown form labor union activity pressure thirdparty interest group risk relate abbvie separation abbott abbvie historical financial information fiscal year prior period necessarily representative result achieve separate publicly trade company reliable indicator future result historical information abbvie annual report fiscal year end december period end prior december refer abbvie business operate integrated abbott abbvie historical financial information period derive consolidated financial statement accounting record abbott accordingly financial information period necessarily reflect financial condition result operation cash flow abbvie achieve separate publicly trade company period present abbvie achieve future additional information past financial performance abbvie business basis presentation financial statement abbvie business item management discussion analysis financial condition result operation item financial statement supplementary data abbvie build information technology infrastructure transition datum system abbvie incur substantial additional cost experience temporary business interruption abbvie installing implement information technology infrastructure support critical business function include accounting reporting manufacturing process control customer service inventory control distribution abbvie incur temporary interruption business operation transition effectively abbott exist transactional operational system datum center transition service support function abbvie replace system abbvie successful implement new system transition datum incur substantially high cost implementation currently anticipate abbvie failure avoid operational interruption implement new system replace abbott information technology service failure implement new system replace abbott service successfully disrupt business adversely affect ability collect receivables customer material adverse effect profitability addition abbvie unable replicate transition certain system ability comply regulatory requirement impaired abbott fail perform transaction agreement execute separation abbvie fail necessary system service place certain transaction agreement expire connection separation abbvie abbott enter separation distribution agreement agreement include transition service agreement tax sharing agreement international commercial operation agreement finish good supply agreement contract manufacturing agreement employee matter agreement special product master agreement information technology agreement transitional trademark license agreement certain agreement provide performance service company benefit period time abbvie separation abbott abbvie rely abbott satisfy performance payment obligation agreement abbott unable satisfy obligation agreement include indemnification obligation abbvie incur operational difficulty loss addition abbvie abbott enter longterm arrangement special product master agreement relate certain product right ex transition service agreement abbott provide abbvie office function service certain market outside united states abbvie establish sufficient office infrastructure conduct operation market arrangement lead dispute abbott abbvie abbvie right certain intellectual property territorial commercialization right allocation cost revenues abbvie product operation outside united states abbvie place systems service abbvie agreement provider service transaction longterm agreement terminate abbvie able operate business effectively profitability decline abbvie process create engage party provide system service replace system service abbott currently provide abbvie successful effectively efficiently implement system service transition datum abbott system abbvie system service expensive efficient system service abbott expect provide transition period abbvie develop implement office function administrative system personnel process market outside united states abbott initially provide function assurance abbvie able fully implement function effectively disrupt business market potential indemnification liability abbott pursuant separation agreement materially adversely affect abbvie separation agreement abbott provide thing principal corporate transaction require effect separation certain condition separation provision govern relationship abbvie abbott respect result separation thing separation agreement provide indemnification obligation design abbvie financially responsible substantially liability certain tax liability exist relate business activity incur prior abbvie separation abbott obligation abbott assume abbvie pursuant separation agreement include relate depakote abbvie require indemnify abbott circumstance set forth separation agreement abbvie subject substantial liability risk relate abbvie common stock abbvie guarantee timing payment dividend common stock abbvie expect pay regular cash dividend time declaration payment future dividend stockholder fall discretion abbvie board director board decision payment dividend depend factor abbvie financial condition earning capital requirement debt service obligation industry practice legal requirement regulatory constraint factor board deem relevant information item market registrant common equity relate stockholder matter issuer purchase equity security abbvie ability pay dividend depend ongoing ability generate cash operation access capital market abbvie guarantee continue pay dividend future abbvie stockholder percentage ownership abbvie dilute future future stockholder percentage ownership abbvie dilute equity issuance capital market transaction equity awards abbvie grant abbvie director officer employee acquisition purpose abbvie employee option purchase share common stock result conversion abbott stock option abbvie stock option abbvie anticipate compensation committee grant additional stock option stockbase award employee award dilutive effect abbvie earning share adversely affect market price abbvie common stock time time abbvie issue additional option stockbase award employee abbvie employee benefit plan addition abbvie amend restate certificate incorporation authorize abbvie issue approval abbvie stockholder class series prefer stock designation power preference relative participate optional special right include preference abbvie common stock respect dividend distribution abbvie board director generally determine term class series prefer stock dilute voting power reduce value abbvie common stock example abbvie grant holder prefer stock right elect number abbvie director event happen specify event right veto specify transaction similarly repurchase redemption right liquidation preference abbvie assign holder prefer stock affect residual value common stock certain provision abbvie amend restate certificate incorporation amend restate bylaw delaware law prevent delay acquisition abbvie decrease trading price abbvie common stock abbvie amend restate certificate incorporation amend restate bylaw contain delaware law contain provision intend deter coercive takeover practice inadequate takeover bid make practice bid unacceptably expensive bidder encourage prospective acquiror negotiate abbvie board director attempt hostile takeover provision include inability abbvie stockholder special meeting division abbvie board director class director class serve stagger threeyear term provision stockholder remove director cause ability abbvie director stockholder fill vacancy abbvie board director requirement affirmative vote stockholder hold percent abbvie voting stock require amend certain provision abbvie amend restate certificate incorporation abbvie amend restate bylaw relate number term election abbvie director fill board vacancy call special meeting stockholder director officer indemnification provision addition section delaware general corporation law provide subject limited exception person acquire affiliated person acquire percent outstanding voting stock delaware corporation shall engage business combination corporation include merger consolidation acquisition additional share threeyear period follow date person affiliate holder percent corporation outstanding voting stock abbvie believe provision protect stockholder coercive unfair takeover tactic require potential acquiror negotiate abbvie board director provide abbvie board director time assess acquisition proposal provision intend company immune takeover provision apply offer consider beneficial stockholder delay prevent acquisition abbvie board director determine good interest abbvie abbvie stockholder provision prevent discourage attempt remove replace incumbent director cautionary statement forwardlooke statement annual report contain certain forward look statement business strategy market potential future financial performance matter word believe expect anticipate project similar expression generally identify forward look statement speak date statement matter discuss forward look statement subject risk uncertainty factor cause actual result differ materially project anticipated imply forward look statement particular information include item business item risk factor item management discussion analysis financial condition result operation contain forward look statement forward look statement expectation belief future result event express expectation belief base current plan expectation abbvie management express good faith believe reasonable basis assurance expectation belief result achieve accomplished factor cause actual result event differ materially anticipate include matter describe item risk factor item management discussion analysis financial condition result operation abbvie undertake obligation update forwardlooke statement include annual report reflect event circumstance date hereof abbvie require applicable security law item b unresolved staff comment item property abbvie corporate office locate north waukegan road north chicago illinois abbvie principal manufacturing plant follow location united states outside united states abbott park illinois campoverde di aprilia italy barceloneta puerto rico cork ireland jayuya puerto rico ludwigshafen germany north chicago illinois sligo ireland worcester massachusetts lease property addition abbvie manufacturing facility united states worldwide abbvie believe facility suitable provide adequate production capacity united states include puerto rico abbvie distribution center abbvie united states research development facility locate abbott park illinois north chicago illinois redwood city california worcester massachusetts outside united states abbvie principal research development facility locate shanghai china ludwigshafen germany note principal plant united states list own abbvie subsidiary abbvie remain manufacturing plant facility own lease abbvie subsidiary abbvie item legal proceeding information pertain legal proceeding provide note entitle legal proceeding contingency note consolidated financial statement include item financial statement supplementary datum incorporate reference item safety disclosure applicable executive officer registrant follow table list abbvie executive officer appoint abbvie corporate officer december indicate age position richard gonzalez chairman board chief executive officer laura j schumacher executive vice president business development external affairs general counsel william j chase executive vice president chief financial officer carlos alban executive vice president commercial operation michael severino md executive vice president research development chief scientific officer timothy j richmond senior vice president human resource azita salekigerhardt phd senior vice president operation thomas hurwich vice president controller appoint corporate officer june mr gonzalez abbvie chairman board chief executive officer serve abbott executive vice president pharmaceutical product group responsible abbott worldwide pharmaceutical business include commercial operation research development manufacturing serve president abbott ventures inc abbott medical technology investment arm mr gonzalez join abbott hold management position briefly retire include abbott president chief operating officer president chief operating officer abbott medical product group senior vice president president abbott hospital product division hospira inc vice president president abbott health system division divisional vice president general manager abbott diagnostic operation united states canada ms schumacher abbvie executive vice president business development external affairs general counsel serve abbott executive vice president general counsel corporate secretary senior vice president corporate secretary general counsel ms schumacher responsible abbott licensing acquisition function office ethic compliance ms schumacher join abbott currently serve director general dynamic corporation mr chase abbvie executive vice president chief financial officer serve abbott vice president license acquisition vice president treasurer divisional vice president controller abbott international mr chase join abbott mr alban abbvie executive vice president commercial operation serve abbott senior vice president proprietary pharmaceutical product global commercial operation senior vice president international pharmaceutical vice president western europe canada vice president european operations mr alban join abbott dr severino abbvie executive vice president research development chief scientific officer dr severino serve amgen inc senior vice president global development corporate chief medical officer vice president global development vice president therapeutic area head general medicine inflammation global clinical development join abbvie mr richmond abbvie senior vice president human resource serve abbott divisional vice president compensation benefit group vice president talent reward divisional vice president talent acquisition mr richmond join abbott dr salekigerhardt abbvie senior vice president operation serve abbott vice president pharmaceutical manufacturing supply divisional vice president quality assurance global pharmaceutical operation dr salekigerhardt join abbott mr hurwich abbvie vice president controller serve abbott vice president internal audit divisional vice president controller abbott diagnostics division mr hurwich join abbott executive officers abbvie elect annually board director officer elect board appoint chairman board officer elect meeting board director hold annual stockholder meeting appoint chairman board board meeting officer hold office successor duly elect appoint qualified officer death resignation removal family relationship executive officer list ii item market registrant common equity relate stockholder matter issuer purchase equity security principal market principal market abbvie common stock new york stock exchange nyse whenissue trading market abbvie common stock begin nyse december regular way trading abbvie common stock begin january prior december public market abbvie common stock abbvie common stock list chicago stock exchange trade regional electronic exchange outside united states abbvie common stock list nyse euronext paris swiss exchange market price share high low high low quarter second quarter quarter fourth quarter stockholder stockholder record abbvie common stock january dividend quarterly dividend pay common stock quarter cash dividend share payable february second fourth quarter dividend share payable august november respectively october abbvie board director declare increase quarterly cash dividend share share payable february stockholders record january quarterly dividend share pay common stock timing declaration payment dividend abbvie future discretion board director depend factor include abbvie financial condition earning capital requirement operating subsidiary covenant associate certain abbvie debt service obligation legal requirement regulatory constraint industry practice ability access capital market factor deem relevant board director abbvie determine pay dividend future assurance continue pay dividend dividend abbvie inc illinois high impact business hib locate federal foreign trade subzone subzone dividend eligible subtraction base income illinois income tax purpose question contact tax advisor performance graph follow graph compare cumulative total return abbvie sp index nyse arca pharmaceuticals index graph cover period january day abbvie common stock begin regularway trading nyse december graph assume invest stock index january assume reinvestment dividend stock price performance follow graph necessarily indicative future stock price performance comparison cumulative total return performance graph furnish shall deem file sec subject section exchange act shall deem incorporate reference filing securities act amend issuer purchase equity security c total number share unit total purchase maximum number number b average publicly approximate dollar value share price announce share unit unit pay share plan purchase period purchase unit program plan programs october october november november december december total share represent share deem surrender abbvie pay exercise price connection exercise employee stock option october november december ii share purchase open market benefit participant abbvie employee stock purchase plan october november december share include share surrender abbvie satisfy minimum tax withholding obligation connection vest restricted stock restrict stock unit authorization supersede previouslydisclose billion stock repurchase program october abbvie announce board director authorize purchase billion common stock time time item select financial datum follow table set forth abbvie select financial information derive audit consolidated financial statement year end december ii audit combine financial statement year end december historical financial statement period prior january prepare standalone basis derive abbott consolidated financial statement accounting record researchbase pharmaceutical business abbott abbvie period present accordingly abbvie financial statement period prior january present combined basis reflect abbvie financial position result operation cash flow business operate abbott prior separation conformity generally accept accounting principle gaap united states historical financial statement period prior january reflect allocation expense relate certain abbott corporate function include senior management legal human resource finance information technology quality assurance expense allocate abbvie base direct usage benefit identifiable remainder allocate pro rata basis revenue headcount square footage number transaction measure abbvie consider expense allocation methodology result reasonable allocation indicative actual expense incur abbvie operate independent standalone publiclytrade company period present accordingly historical financial information present period prior january indicative result operation financial position achieve abbvie independent standalone publiclytrade company period show abbvie performance period subsequent december refer separation abbott laboratories basis historical presentation transition abbott cost operate independent company include item management discussion analysis financial condition result operation additional information select financial information read conjunction financial statement accompany note include item financial statement supplementary datum item management discussion analysis financial condition result operation year end december millions share datum statement earning datum net sale net earningsa basic earning sharea diluted earning sharea cash dividend declare share b na na na weightedaverage basic share outstandingc weightedaverage dilute share outstandingc balance sheet datum total asset longterm debt lease obligationsd result year end december include high expense associate operate independent standalone publicly trade company historically derive financial statement increase include impact interest expense debt issue november high tax rate year incremental cost operate independent company addition result year end december include aftertax transaction financingrelated cost total billion share incur connection terminate propose combination shire plc shire million aftertax charge relate research development collaboration agreement calico life sciences llc calico million aftertax charge result enter global collaboration infinity pharmaceuticals inc infinity refer note audit consolidated financial statement include item financial statement supplementary datum information relate termination propose combination shire collaboration calico infinity respectively b abbvie declare regular quarterly cash dividend aggregate share common stock addition cash dividend share common stock declare preseparation earning january record reduction additional pay capital refer note audit consolidated financial statement include item financial statement supplementary datum additional information cash dividend declare c january abbott distribute million share abbvie common stock period prior separation weight average basic diluted share outstanding base number share abbvie common stock outstanding distribution date refer note audit consolidated financial statement include item financial statement supplementary data information calculation basic diluted earning common share year end december include current portion longterm debt lease obligation item management discussion analysis financial condition result operation follow discussion analysis financial condition abbvie inc abbvie company result operation year period end december commentary read conjunction consolidated financial statement accompany note appear item financial statement supplementary data executive overview company overview abbvie global researchbase biopharmaceutical company abbvie develop market advanced therapy address world complex disease abbvie product treat chronic autoimmune disease include rheumatoid arthritis psoriasis crohn disease hepatitis c hcv human immunodeficiency virus hiv endometriosis thyroid disease parkinson disease complication associate chronic kidney disease ckd cystic fibrosis health condition low testosterone abbvie pipeline promise new medicine include compound indication phase phase development important medical specialty immunology virologyliver disease oncology renal disease neurological disease woman health abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse united states abbvie distribute pharmaceutical product principally independent wholesale distributor sale directly pharmacie patient outside united states sale directly customer distributor depend market serve certain product comarkete copromote company abbvie approximately employee product sell country abbvie operate business segmentpharmaceutical product financial result independent company abbvie strategy focus deliver strong financial result return shareholder ensure strong sustainable growth business long term abbvie grow worldwide net sale percent billion drive primarily continue strength humira doubledigit sale growth key product include creon duodopa synthroid sale growth continue reflect impact loss exclusivity company lipid franchise result loss million revenue prior year generic competition begin november tricor july trilipix september niaspan company financial performance include deliver fully dilute earning share include aftertax transaction financingrelated cost total billion incur connection terminate propose combination shire plc shire million aftertax charge relate research development collaboration agreement calico life sciences llc calico million aftertax charge result enter global collaboration infinity pharmaceuticals inc infinity refer note information termination company propose combination shire note information company collaboration calico infinity abbvie financial performance reflect improvement gross margin primarily favorable product mix product portfolio operational efficiency increase funding support abbvie emerge midand latestage pipeline asset additional humira indication company generate cash flow operation billion net aftertax transaction financingrelated cost incur connection terminate propose combination shire strong cash flow enable company continue enhance pipeline licensing collaboration activity pay cash dividend shareholder billion repurchase approximately million share million addition board director declare increase company quarterly cash dividend share share common stock payable february authorize new billion stock repurchase program expect execute year addition financial result abbvie continue advance pipeline include secure regulatory approval united states abbvie interferonfree hcv treatment viekira pak submit regulatory application european union subsequently approve january abbvie continue advance previously submit regulatory application united states duopa subsequently approve january complete latestage clinical trial include zinbryta daclizumab treatment relapsingremitte form multiple sclerosis ms registrational program expand use humira hidradenitis suppurativa abbvie augment pipeline strategic licensing partnering activity include inlicense duvelisib dual acting pi kinase inhibitor currently investigation use variety hematological malignancy infinity enter novel collaboration calico discover develop commercialize new therapy patient agerelate disease strategic objective abbvie expect sale performance drive continued strong growth humira launch viekira pak sale growth certain key product include creon duodopa partially offset decline product generic competition include androgel remainder lipid franchise addition abbvie expect achieve operating margin improvement continue invest pipeline support opportunity oncology hcv immunology continue investment key product abbvie expect grow operate cash flow enable company continue augment pipeline concert focus strategic licensing acquisition partnering activity return cash shareholder dividend share repurchase abbvie expect continue drive strong humira sale growth way abbvie seek expand humira patient base apply regulatory approval new indication humira treat condition uveiti hidradenitis suppurativa abbvie seek drive humira sale growth expand market share presence underserve market abbvie plan continue make investment key emerge market include brazil china russia key driver abbvie performance viekira pak approve united states european union number country world abbvie expect support successful launch viekira united states secure payor position patient access focus commercial effort penetration abbvieexclusive parity account company launch viekirax european country include germany united kingdom canada continue work government world gain reimbursement approval abbvie continue investment product historically stable sale level make adjustment necessary increase value product portfolio abbvie plan achieve objective variety way depend product circumstance example identify supply chain efficiency pursue additional indication optimize residual value product reach end exclusivity abbvie believe approach allow company maintain strong operating margin rd effort continue focus significant portion expenditure compound immunology virologyliver disease oncology renal disease neurological disease woman health abbvie scientist work advance pipeline specialty molecule demonstrate strong clinical performance patient economic value patient healthcare system current rd project describe research development section abbvie continue augment pipeline concert focus strategic licensing acquisition partner activity research development research innovation continue key strategic priority abbvie abbvie longterm success depend great extent ability continue discover develop innovative pharmaceutical product acquire collaborate compound currently development biotechnology pharmaceutical company abbvie pipeline include compound indication clinical development individually collaboration license agreement program approximately phase development registration abbvie expect multiple phase program transition phase program rd focused therapeutic area include immunology virologyliver disease oncology renal disease neurological disease woman health immunology humira approve treat follow autoimmune disease united states canada mexico collectively north america european union condition principal market rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylose spondylitis north america european union crohn disease moderate severe north america european union plaque psoriasis moderate severe north america european union juvenile idiopathic arthritis north america european union ulcerative colitis moderate severe united states european union axial spondyloarthropathy united states european union pediatric crohn disease severe united states european union pediatric enthesitisrelate arthritis european union abbvie continue dedicate rd effort expand indication humira include field gastroenterology dermatology ophthalmology phase trial ongoing preparation regulatory application humira uveitis united states european union regulatory application hidradenitis suppurativa file united states european union abbvie number nextgeneration program underway address immunemediate condition include follow abbvie study dual variable domain immunoglobulin dvdig technology represent approach target multiple disease cause antigen single biologic agent continue progress proprietary technology lead nextgeneration biologic treatment complex condition cancer rheumatoid arthritis multiple pathway involve disease abt dvd direct il tnf currently phase investigation ra abt dvd target il alpha beta study osteoarthritis ongoing phase program abbvie collaborate biotest ag anticd biologic know tregalizumab compound currently phase b clinical trial rheumatoid arthritis psoriasis filgotinib glpg nextgeneration oral janus kinase jak inhibitor develop galapagos nv galapagos collaboration enter quarter filgotinib currently phase b development treat rheumatoid arthritis able address autoimmune disease january phase study evaluate filgotinib treat crohn disease initiate abt abbvie jak selective inhibitor currently phase b september abbvie enter global collaboration ablynx nv ablynx develop commercialize antiilr nanobody alx treat inflammatory disease include rheumatoid arthritis systemic lupus erythematosus alx currently phase development rheumatoid arthritis abbvie enter global collaboration alvine pharmaceuticals inc alvine develop alv novel oral treatment patient celiac disease alv currently phase b development virologyliver disease december food drug administration fda approve abbvie viekira pak alloral interferonfree treatment ribavirin rbv treatment patient chronic genotype hcv infection include compensate cirrhosis january abbvie announce european commission grant marketing authorization alloral shortcourse interferonfree treatment viekirax ombitasvirparitaprevirritonavir tablet exviera dasabuvir tablet treatment approve rbv patient genotype chronic hcv infection include compensate liver cirrhosis hiv coinfection patient opioid substitution therapy liver transplant recipient additionally viekirax approve use rbv genotype chronic hcv patient abbvie hcv combination phase development japan abbvie submit regulatory application japan abbvie currently conduct phase study nextgeneration hcv program include abt potent protease inhibitor abt abbvie new nsa inhibitor oncology abbvie focus development target treatment inhibit tumor growth improve response common cancer therapy abbvie laterstage oncology pipeline include follow elotuzumab antislam antibody treatment multiple myeloma collaboration bristolmyer squibb bms phase development begin june multiple myeloma abbvie bms announce fda grant elotuzumab breakthrough therapy designation use combination lenalidomide dexamethoasone treatment multiple myeloma patient receive prior therapy phase study ongoing result expect veliparib abt parpinhibitor phase study brcamutate breast cancer treat chemotherapy initiate veliparib phase evaluation treatment variety solid tumor abbvie announce initiation separate phase clinical trial evaluate safety efficacy veliparib combination chemotherapy patient previously untreate locally advanced metastatic squamous nonsmall cell lung cancer nsclc separate study patient nonsquamous nsclc neoadjuvant therapy add carboplatin prior surgery woman earlystage triple negative breast cancer patient human epidermal growth factor receptor negative metastatic locallyadvance breast cancer contain brca andor brca gene mutation add carboplatin paclitaxel venetoclax abt nextgeneration bcl inhibitor development patient relapsedrefractory chronic lymphocytic leukemia phase study chronic lymphocytic leukemia cll initiate collaboration abbvie development partner roche holding ag abbvie complete enrollment single arm study evaluate venetoclax patient relapsedrefractory cll harbor p deletion mutation negative prognostic factor abbvie anticipate result study venetoclax explore use number different hematologic cancer include nonhodgkin lymphoma diffuse large bcell lymphoma acute myeloid leukemia molecular target explore antibodydrug conjugate approach link antitarget antibodie potent cytotoxic agent european medicine agency ema fda grant orphan drug designation abbvie investigational compound abt antiepidermal growth factor receptor antibody drug conjugate evaluate safety efficacy patient glioblastoma multiforme common aggressive type malignant primary brain tumor abbvie inlicense duvelisib dual acting pi kinase inhibitor currently investigation use variety hematological malignancy infinity duvelisib investigation use indolent nonhodgkin lymphoma use cll renal disease abbvie renal care pipeline include atrasentan prevention progression diabetic ckd phase study initiate assess atrasentan add standard care progression kidney disease patient stage ckd type diabete global registrational study expect complete atrasentan potentially compound launch treat diabetic nephropathy specifically target albuminuria slow progression ckd abbvie previously investigate abt treatment acute kidney injury associate major cardiac vascular surgery abbvie complete phase b study base result study decide continue development abt neurological disease abbvie clinical study underway multiple compound target receptor brain help regulate mood memory neurological function condition include follow abbvie collaborate biogen idec develop zinbryta daclizumab treatment relapsingremitte form ms common form affect nearly percent newly diagnose ms patient phase study zinbryta daclizumab anticd monoclonal antibody successfully complete abbvie process work biogen idec complete global regulatory application zinbryta daclizumab expect submit half january abbvie announce fda approve duopa levodopacarbidopa intestinal gel treatment parkinson disease duopa administer small portable infusion pump deliver levodopa carbidopa directly small intestine continuous hour procedurallyplaced tube product sell duodopa outside united states abbvie complete phase b study abt annr modulator alzheimer disease cognitive impairment associated schizophrenia base result study abbvie plan advance molecule indication woman health abbvie develop novel oral gonadotropinrelease hormone gnrh antagonist elagolix collaboration neurocrine bioscience treatment endometriosisrelate pain uterine fibroid phase study endometriosis begin mid second phase trial endometriosis initiate positive topline efficacy result initial phase study recently announce additional safety efficacy datum expect phase study uterine fibroid initiate november transition phase b give numerous source potential future growth individual project expect material cash flow result operation year factor consider include rd expense project incurred project year relative abbvie total rd expense qualitative factor marketplace perception impact new product abbvie overall market position delay abbvie rd activity expect material impact operation aggregate cost complete numerous pharmaceutical project currently development expect material total cost complete depend abbvie ability successfully complete project rate project advance nature extent costshare arrangement ultimate timing completion give potential significant delay high rate failure inherent research development new pharmaceutical product possible accurately estimate total cost complete project currently development separation abbott laboratories basis historical presentation abbvie incorporate delaware april january abbvie independent publiclytraded company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott shareholder prior separation historical financial statement prepare standalone basis derive abbott consolidated financial statement accounting record researchbase pharmaceutical business abbott abbvie period present accordingly abbvie financial statement period prior january present combined basis reflect abbvie financial position result operation cash flow business operate abbott prior separation conformity generally accept accounting principle gaap united states combine financial statement principally represent historical result operation asset liabilitie abbott researchbase pharmaceutical business period prior january historical combine financial statement reflect allocation expense relate certain abbott corporate function include senior management legal human resource finance information technology quality assurance expense allocate abbvie base direct usage benefit identifiable remainder allocate pro rata basis revenue headcount square footage number transaction measure abbvie consider expense allocation methodology result reasonable allocation indicative actual expense incur abbvie operate independent standalone publiclytrade company period present accordingly historical financial information present period prior january indicative result operation financial position achieve abbvie independent standalone publiclytrade company period show abbvie performance period subsequent december result operation net sale comparison present constant currency rate reflect comparative local currency sale prior year foreign exchange rate measure provide information change net sale assume foreign currency exchange rate change prior current period abbvie believe nongaap measure change net sale constant currency rate conjunction gaap measure change net sale actual currency rate provide complete understand company operation facilitate analysis company result operation particularly evaluate performance period percent change actual constant currency currency rate rate year end millions united states international net sale sale growth drive continued strength humira united states internationally sale growth key product include synthroid creon duodopa sale increase despite loss exclusivity abbvie consolidated lipid franchise unfavorable impact foreign exchange rate generic competition begin november tricor july trilipix september niaspan follow table detail sale key product percent change actual constant currency currency rate rate year end december millions humira united states international total androgel united states kaletra united states international total synagis international lupron united states international total synthroid united states sevoflurane united states international total creon united states dyslipidemia product united states duodopa international viekira pak united states total constant currency basis global humira sale increase percent percent primarily result market growth therapeutic category geographie approval new indication high market share favorable pricing certain geography abbvie pursue new indication help differentiate humira compete product add sustainability future growth humira androgel sale decrease percent primarily decline overall testosterone replacement market company expect trend continue androgel sale impact rebate implement second half certain account loss early moderation market growth experience androgel sale expect impact generic competition early global sale kaletra decline primarily low market share result impact increase competition hiv marketplace sale synagis increase percent primarily increase product uptake compare respectively synthroid sale increase percent percent respectively strong brand loyalty market leadership favorable pricing sale sevoflurane relatively flat decline percent continue impact generic competition sale creon grow percent percent respectively primarily drive market growth high market share creon maintain market leadership pancreatic enzyme market sale abbvie consolidated lipid franchise include tricor trilipix niaspan simcor advicor decline percent percent introduction generic version product market generic competition begin november tricor july trilipix september niaspan sales duodopa abbvie therapy advanced parkinson disease approve europe international market increase percent percent duopa regulatory submission united states approve fda january abbvie launch hcv regiman viekira pak united states follow fda approval middecember sale viekira pak reflect shipment launch quantity market support commercial launch january european commission grant marketing authorization abbvie hcv regimen viekirax ombitasvirparitaprevirritonavir tablet exviera dasabuvir tablets january abbvie expect hcv regimen significant contributor sale growth gross margin percent change year end december millions gross margin net sale gross margin reflect favorable impact product mix product portfolio include humira operational efficiency price increase low amortization expense intangible asset partially offset effect unfavorable foreign exchange rate loss exclusivity lipid franchise gross margin include royalty income million relate prior period result settlement licensing arrangement partially offset million impairment charge intangible asset sell general administrative percent change year end december million sell general administrative net sale sga expense include transactionrelated cost total billion incur connection terminate propose combination shire refer note note consolidated financial statement include item financial statement supplementary data information termination company propose combination shire exclude shire break fee transactionrelated cost increase sga expense primarily increase selling marketing support new product include preparation expect launch viekira pak spending relate new indication geographic expansion humira increase partially offset impact favorable foreign exchange rate sga expense include million million million respectively cost associate separation abbvie abbott sga expense include million charge additional expense relate brand prescription drug fee july internal revenue service issue final rule regulation brand prescription drug fee annual nontaxdeductible fee payable federal government affordable care act base allocation company market share brand prescription drug sell certain government program prior year final rule accelerate expense recognition criterion fee obligation year fee pay year market share allocate fee determine change require abbvie industry participant recognize additional year expense result additional expense million recognize final rule regulation change time annual fee pay sga expense include restructuring charge aggregate million principally relate restructure certain commercial operation conjunction loss expect loss exclusivity certain product include litigation charge million relate investigation sale marketing activity depakote resolve research development acquire inprocess research development percent change year end december million research development net sale acquire inprocess research development rd expense reflect funding support company emerge mid latestage pipeline asset continue pursuit additional humira indication increase partially offset impact favorable foreign exchange rate fluctuation rd expense include regulatory milestone payment million million relate company collaboration rd expense include restructuring charge million million acquire inprocess research development iprd expense principally include charge million result enter global collaboration infinity develop commercialize duvelisib treatment patient cancer refer note acquisition collaboration arrangement note consolidated financial statement include item financial statement supplementary datum additional information relate company collaboration arrangement iprd expense principally include charge million result enter global license agreement ablynx develop commercialize alx charge million result enter global collaboration alvine develop alv charge million result enter global collaboration galapago cystic fibrosis therapie charge total million result enter arrangement iprd expense include charge million acquisition abt charge million result enter global collaboration develop commercialize oral nextgeneration jak inhibitor charge million result enter twoyear collaboration agreement research develop commercialize compound antibodydrug conjugate approach expense expense consist million charge relate rd collaboration agreement calico discover develop commercialize new therapy patient agerelate disease interest expense net interest expense net million million million comprise primarily interest expense outstanding debt november abbvie issue billion longterm debt maturity range year enter interest rate swap financial institution convert billion fix rate interest rate debt float interest rate debt commercial paper outstanding december million million billion respectively interest expense net include million financing relate fee incur connection terminate propose combination shire bridge facility fee relate separation abbott income net income net include income resolution certain contractual agreement fair value adjustment contingent consideration impairment equity security income net primarily consist income million resolution contractual agreement income tax expense effective income tax rate percent percent percent effective tax rate fluctuate year year allocation company taxable earning jurisdiction certain discrete factor event year include acquisition collaboration increase effective income tax rate principally drive state valuation allowance million additional expense million relate brand prescription drug fee nondeductible increase effective tax rate principally income tax expense relate certain earning outside united states expect indefinitely reinveste absence million tax benefit record result favorable resolution tax position pertain prior year transition abbott cost operate independent company abbvie continue incur additional ongoing operating expense operate independent company include cost corporate headquarters function incremental information technologyrelate cost incremental cost operate standalone office infrastructure outside united states abbvie transition service agreement abbott united states cover certain corporate support service abbvie historically receive abbott service include information technology account payable payroll financial function engineering support facility quality assurance support administrative service term service agreement vary activity agreement facilitate separation allow abbvie operate independently prior establish standalone office function organization date separation abbvie sufficient office infrastructure operate market outside united states result abbvie enter transition service agreement abbott provide service outside united states include office service certain country year separation office service include information technology account payable payroll receivables collection treasury financial function order entry warehouse administrative service transition service agreement allow abbvie operate international pharmaceutical business independently prior establish standalone office infrastructure country transition abbott abbvie continue incur nonrecurring expense expand international infrastructure addition certain international market date separation december certain marketing authorization sell abbvie product continue hold abbott authorization transfer applicable regulatory channel practicable estimate cost incur period present historical financial statement function describe actual cost incur abbvie operate standalone company period depend factor include organizational design outsource strategic decision relate corporate function information technology international office infrastructure refer note entitle background basis presentation note consolidated financial statement include item financial statement supplementary datum description transaction abbvie abbott financial position liquidity capital resource year end december million cash flow provide byused operating activity invest activity financing activity cash flow provide operation billion compare billion decrease primarily aftertax transaction finance relate cost billion incur connection termination propose combination shire include net foreign exchange loss relate settlement undesignate forward contract hedge anticipate foreign currency cash outflow exit certain foreign currency position decrease time wholesaler collection investment inventory preparation launch abbvie interferon free hcv combination united states start middecember european union january decrease increase abbvie voluntary contribution main domestic define benefit pension plan million million abbvie voluntary contribution million plan subsequent december cash outflow relate collaboration acquisition arrangement total million include million pay infinity relate global collaboration develop duvelisib ipi million fund novel rd collaboration calico abbvie accrue additional million payment calico satisfaction certain condition rd collaboration subsequently pay cash outflow relate collaboration acquisition arrangement total million include million relate global collaboration ablynx nv million relate global collaboration alvine cash flow investing activity reflect capital expenditure include purchase small molecule active pharmaceutical ingredient manufacturing facility singapore net sale purchase shortterm investment company issue redeem commercial paper balance commercial paper outstanding million million december respectively abbvie issue additional commercial paper retire commercial paper meet liquidity requirement need cash dividend payment total billion billion october board director declare quarterly cash dividend share stockholder record close business january payable february time declaration payment dividend discretion abbvie board director depend factor include abbvie financial condition earning capital requirement operating subsidiary covenant associate certain abbvie debt service obligation legal requirement regulatory constraint industry practice ability access capital market factor deem relevant board director february abbvie board director authorize billion common stock repurchase program effective immediately october abbvie board director authorize new billion stock repurchase program effective immediately supersede prior authorization program company repurchase approximately million share million open market approximately million share million open market purchase abbvie share time time management discretion program time limit discontinue time abbvie remain share repurchase authorization billion december cash equivalent impact net unfavorable exchange rate change total million principally impact substantial weakening euro translation company eurodenominate asset weaken foreign currency combination increase concentration cash denominate foreign currency accumulate anticipation terminate propose combination shire significant portion cash equivalent december consider reinveste indefinitely foreign subsidiary abbvie expect reinvestment affect liquidity capital resource fund need operation united states abbvie require accrue pay income taxis repatriate fund abbvie believe sufficient source liquidity support assumption disclose undistribute earning december reinveste indefinitely substantially abbvie trade receivables greece portugal italy spain governmental health system abbvie continue monitor economic health economy southern europe heighten economic concern exist outstanding net governmental receivables country december follow net receivables year net receivable past million greece portugal italy spain total abbvie monitor economic condition creditworthiness customer government regulation fund domestically abroad abbvie regularly communicate customer status receivable balance include payment plan obtain positive confirmation validity receivables abbvie establishe allowance account receivable probable collect abbvie monitor potential periodically utilize factoring arrangement mitigate credit risk receivable include arrangement historically material total outstanding receivables currently abbvie believe economic condition southern europe material impact company liquidity cash flow financial flexibility government funding unavailable country significant adverse change reimbursement practice occur abbvie able collect entire balance outstanding december credit facility access capital credit rating credit facility prior october abbvie party billion unsecured fiveyear revolve credit facility syndicate lender support commercial paper borrowing credit facility enable company borrow fund float interest rate october abbvie replace exist revolve credit facility new billion fiveyear revolve credit facility new revolve credit facility enable company borrow fund unsecured basis variable interest rate contain covenant december company compliance credit facility covenant commitment fee credit facility material amount outstanding credit facility december access capital company intend fund shortterm longterm financial obligation mature cash hand future cash flow operation issue additional debt company ability generate cash flow operation issue debt enter financing arrangement acceptable term adversely affect material decline demand company product solvency customer supplier deterioration company key financial ratio credit rating material unfavorable change business condition current time company believe sufficient financial flexibility issue debt enter financing arrangement attract longterm capital acceptable term support company growth objective credit rating july follow announcement propose combination shire moody investor service affirm baa senior unsecured longterm rating prime shortterm rating revise rating outlook stable positive addition standard poor rating service sp place corporate credit rating senior unsecured debt rating abbvie creditwatch negative implication october sp affirm abbvie corporate credit rating senior unsecured debt rating remove negative credit watch sp affirm commercial paper rating place creditwatch change company credit rating unfavorable change rating adverse impact future financing arrangement affect company ability draw credit facility result acceleration schedule maturities company outstanding debt contractual obligation follow table summarize abbvie estimate contractual obligation december million total year year year year shortterm borrowing research development collaborationsa longterm debt capital lease obligation include current portion interest longterm debtb future minimum noncancelable operating lease commitment purchase obligation otherc longterm liabilitiesd total account payable accrue liability include million accrual payment calico satisfaction certain condition rd collaboration pay quarter b include estimate future interest payment longterm debt security capital lease obligation interest payment debt calculate future period interest rate effect end project interest payment include relate effect interest rate swap agreement certain project interest payment differ future base change float interest rate factor event project interest payment pertain obligation agreement outstanding december refer note discussion company debt instrument relate interest rate agreement outstanding december annual interest capital lease obligation material c include company significant unconditional purchase obligation commitment exceed company project requirement normal course business amount year include voluntary contribution million abbvie main domestic define benefit plan subsequent december amount exclude pension postemployment benefit relate deferred compensation cash outflow time fund uncertain dependent future movement interest rate investment return change law regulation variable include component longterm liability include restructuring refer note information abbvie enter rd collaboration arrangement party require future milestone payment party contingent achievement certain development regulatory commercial milestone individually arrangement material annual reporting period milestone multiple product cover arrangement happen reach reporting period aggregate charge expense material result operation period business perspective payment view positive signify product successfully move development generating likely generate cash flow product sale possible predict reasonable certainty milestone achieve timing achievement result potential payment include table contractual obligation refer note consolidated financial statement discussion collaboration arrangement critical accounting policy estimate preparation financial statement accordance generally accept accounting principle require use estimate assumption affect report amount asset liability report amount revenue expense summary company significant accounting policy include note consolidated financial statement certain policy consider critical significantly impact company financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain actual result vary estimate revenue recognition abbvie recognize revenue persuasive evidence arrangement exist delivery occur sale price fix determinable collectability sale price reasonably assure revenue product sale recognize title risk loss pass customer rebate abbvie provide rebate pharmacy benefit management company state agency administer federal medicaid program insurance company administer medicare drug plan wholesaler group purchasing organization government agency private entity rebate amount usually base volume purchase contractual statutory price product type rebate factor calculation accrual rebate include identification product sell subject rebate customer government agency price term apply rebate estimate lag time sale payment rebate historical trend rebate adjust current change abbvie estimate rebate pay record liability reduction gross sale abbvie record sale product settlement rebate generally occur month sale abbvie regularly analyze historical rebate trend make adjustment reserve change trends term rebate program rebate chargeback accruals record period relate sale reflect reduction sale rebate chargeback total billion billion billion respectively percent percent percent respectively gross sale subject rebate onepercentage point increase percentage rebate relate annual gross sale decrease net sale million abbvie consider percentage point increase reasonably likely increase percentage rebate relate gross sale allowance cash discount return charge gross sale million million million respectively management analyze adequacy end rebate accrual balance quarter united states significant charge gross sale medicaid medicare rebates manage care rebate wholesaler chargeback medicaid rebate relate federal medicaid program administer state agency rebate provide participate state local government entity law regulation case supplemental rebate provide state contractual agreement medicare rebate negotiate manage care organization manage prescription drug plan cover medicare drug benefit pharmacy benefit manager rebate arise contractual agreement private health care plan seek reduce cost negotiate discount pharmaceutical manufacturer wholesaler chargeback programs wholesaler charge abbvie difference price pay wholesaler abbvie price pay end customer wholesaler contractual discount agreement negotiate abbvie end customer order evaluate adequacy end accrual balance type rebate management use internal external datum estimate level inventory distribution channel rebate claim processing lag time rebate external data source estimate inventory distribution channel include inventory level periodically report wholesaler management estimate process lag time base periodic sampling claim datum estimate rebate percentage net price system calculation track sale product customer payer estimate contractual statutory rebate net price abbvie believe system calculation reliable follow table analysis large rebate accrual chargeback allowance comprise approximately percent total consolidated rebate provision charge revenue remain rebate provision charge gross sale significant determination operating earning medicaid manage medicare care wholesaler millions rebate rebate chargeback balance december provision payment balance december provision payment balance december provision payment balance december historically adjustment prior year rebate accrual material net income abbvie employ technique verify accuracy claim submit possible work organization submit claim gain insight change affect rebate amount medicaid medicare government agency program calculation rebate involve interpretation relevant regulation subject challenge change interpretation cash discount return cash discount reliably estimate product return reliably estimate abbvie historical return low sale return term sale term remain relatively unchanged period pension postemployment benefit abbvie engage outside actuary assist determination obligation cost plan direct obligation abbvie valuation fund status net periodic benefit cost plan calculate actuarial assumption significant assumption review annually include discount rate expect longterm rate return plan asset health care cost trend rate significant assumption determine calculation disclose note consolidated financial statement discount rate select base current market rate highquality fixedincome investment december year abbvie employs yieldcurve approach country robust bond market exist yield curve develop highquality bond discount rate single rate equate discount cash flow rate utilize yield curve result yieldcurve approach reflect specific cash flow plan ie duration calculate discount rate country abbvie review index corporate bond government bond benchmark estimate discount rate abbvie assumed discount rate significant effect amount report define benefit pension postemployment plan december calculation net periodic benefit cost basis point change assume discount rate follow effect abbvie calculation net periodic benefit cost project benefit obligation december basis point million increase decrease define benefit plan service cost interest cost project benefit obligation postemployment plan service cost interest cost project benefit obligation expect longterm rate return base asset allocation historical performance current view expect future return abbvie consider input longterm focus avoid shortterm market influence current longterm rate return plan asset support historical performance trust actual target asset allocation abbvie assume expected longterm rate return significant effect amount report define benefit pension plan december calculation net periodic benefit cost december percentage point change assume expected longterm rate return plan asset increase decrease net period benefit cost plan million health care cost trend rate select review historical trend current view project future health care cost increase current health care cost trend rate support historical trend experience plan assume health care cost trend rate significant effect amount report health care plan december calculation net periodic benefit cost percentage point change assume health care cost trend rate follow effect abbvie calculation net periodic benefit cost project benefit obligation december percentage point million increase decrease service cost interest cost project benefit obligation income taxis abbvie account income taxis asset liability method provision federal state foreign income taxis calculate report pretax earning base current tax law defer taxis provide enact tax rate future tax consequence temporary difference difference financial statement carry asset liability respective tax basis tax benefit carryforward valuation allowance establish maintain base currently available information likely portion defer tax asset realize litigation company subject contingency legal proceeding claim arise normal course business refer note information loss contingency provision record probable loss management good estimate loss good estimate minimum loss contingency probable range record accordingly abbvie initially unable develop good estimate loss minimum zero record information know minimum loss increase result additional loss provision good estimate result additional loss provision occasionally good estimate change low event result expectation favorable outcome previously expect significant litigation reserve december valuation goodwill intangible asset abbvie acquire continue acquire significant intangible asset connection business combination abbvie record fair value transaction involve purchase sale intangible asset occur frequency company pharmaceutical industry valuation usually base discount cash flow analysis incorporate stage completion discount cash flow model require assumption time future net cash flow risk cost capital terminal value market participant factor significantly affect value intangible asset iprd acquire business combination capitalize indefinitelive intangible asset regulatory approval obtain time account definitelived asset amortize estimate useful life iprd acquire transaction business combination expense immediately deem alternative future use payment party subsequent regulatory approval capitalize amortize remain useful life abbvie review recoverability definitelive intangible asset event change circumstance indicate carry value asset recoverable goodwill indefinitelive intangible asset relate iprd review impairment annually event result impairment occur refer note consolidated financial statement information annually company test goodwill impairment assess qualitative factor determine likely fair value carrying factor consider assessment include general macroeconomic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance sustained decline company share price company conclude likely fair value report unit carrying quantitative impairment test perform abbvie test indefinitelive intangible asset quantitative impairment test quantitative impairment test company use estimate future cash flow approach require significant judgment respect future volume revenue expense growth rate change work capital use foreign currency exchange rate selection appropriate discount rate asset grouping assumption estimate estimate assumption consistent company business plan market participant view company similar company use alternative estimate assumption increase decrease estimate fair value asset potentially result different impact company result operation actual result differ company estimate december goodwill intangible asset net amortization total billion billion respectively amortization expense intangible asset million million million respectively impairment goodwill abbvie record impairment charge million relate certain onmarket product right japan increase generic competition charge include cost product sell abbvie record impairment charge million certain project development charge include rd expense impairment charge record recent accounting pronouncement financial accounting standard board issue accounting standard update asu summary amendment create revenue contract customer topic asset defer costscontract customer subtopic amendment asu supersede current revenue recognition requirement core principal new guidance entity recognize revenue depict transfer promise good service customer reflect consideration entity expect entitled exchange good service guidance effective annual reporting period begin december include interim period reporting period early application permit abbvie apply amendment follow method retrospectively prior reporting period present ii retrospectively cumulative effect initially apply amendment recognize date initial application abbvie currently assess impact adopt guidance consolidated financial statement item quantitative qualitative disclosure market risk company expose risk earning cash flow equity adversely impact change foreign exchange rate interest rate certain derivative instrument available costeffective basis hedge company underlie economic exposure refer note entitle financial instrument fair value measure note consolidated financial statement include item financial statement supplementary data information company financial instrument hedge strategy foreign currency risk abbvie primary net foreign currency exposure euro british pound japanese yen abbvie foreign subsidiary enter foreign currency forward exchange contract manage exposure change foreign exchange rate anticipate transaction denominate currency functional currency local entity contract designate cash flow hedge variability cash flow change foreign currency exchange rate markedtomarket result gain loss reflect accumulated comprehensive loss abbvie consolidated balance sheet defer gain loss contract include cost product sell time product sell party generally exceed month december abbvie hold billion billion respectively notional amount contract abbvie enter foreign currency forward exchange contract manage exposure foreign currency denominate trade payable receivables intercompany loan contract designate hedge markedtomarket result gain loss reflect net foreign exchange abbvie consolidated statement earning generally offset loss gain foreign currency exposure manage december abbvie hold notional amount billion billion respectively foreign currency forward exchange contract follow table reflect total foreign currency forward contract outstanding december fair fair weighted carrying weight carry average value average value contract exchange receivable contract exchange receivable million rate payable rate payable receive primarily dollar exchange follow currency euro british pound japanese yen currency na na total company estimate percent appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million december realize appreciation negatively affect earning remain life contact percent appreciation believe reasonably possible nearterm change foreign currency gain loss hedge instrument offset loss gain hedge transaction reduce earning stockholder equity volatility relate foreign exchange company estimate percent depreciation abbvie significant foreign currency position dollar cause foreign exchange loss cash shortterm investment million december percent depreciation believe reasonably possible nearterm change currency company venezuelan operation continue report dollar functional currency hyperinflationary status venezuelan economy currency restriction enact venezuela require abbvie obtain approval venezuelan government exchange venezuelan bolivar dollar require exchange official exchange rate establish government effective february venezuelan government devalue official exchange rate result loss million record net foreign exchange loss consolidate statement earning quarter venezuelan government expand number exchange mechanism rate exchange december cencoex rate official rate sicad rate approximately sicad ii rate approximately february venezuelan government confirm official exchange rate venezuelan bolivar dollar settlement food medicine purchase company continue use official rate venezuelan bolivar dollar report venezuela financial position result operation cash flow company believe nature abbvie business operation qualify official rate permit law company predict devaluation venezuelan currency use official rate continue support evolve fact circumstance circumstance change company conclude appropriate use different rate devaluation official rate occur result significant change abbvie result operation december abbvie approximately million net monetary asset denominate venezuelan bolivar convert rate vefusd venezuelan entity net sale million abbvie net monetary asset denominate venezuelan bolivar convert rate vefusd december resulted devaluation loss million interest rate risk interest rate swap manage company exposure change interest rate fair value fixedrate debt effect hedge change fix interest rate variable rate abbvie use derivative instrument interest rate swap manage exposure change interest rate investment security december abbvie interest rate hedge contract total billion company estimate increase interest rate basis point decrease fair value interest rate swap contract approximately million december realize fair value reduction affect earning remain life contract company estimate increase basis point longterm interest rate decrease fair value longterm debt million december basis point change believe reasonably possible nearterm change interest rate market price sensitive investment abbvie hold equity security strategic technology acquisition trade public stock exchange fair value investment approximately million million december respectively abbvie monitor investment temporary decline market value charge impairment loss income temporary decline value occur hypothetical percent decrease share price investment immaterial decrease fair value december percent decrease believe reasonably possible nearterm change share price nonpublicly trade equity security abbvie hold equity security strategic technology acquisition trade public stock exchange carry value investment approximately million million december respectively abbvie monitor investment temporary decline market value charge impairment loss income temporary decline estimate value occur item financial statement supplementary datum consolidate financial statement consolidate statement earning consolidate statement comprehensive income consolidate balance sheet consolidate statement equity consolidate statement cash flow note consolidated financial statement report independent register public accounting firm report independent register public accounting firm abbvie inc subsidiary consolidate statement earning year end december millions share datum net sale cost product sell sell general administrative research development acquire inprocess research development expense total operating cost expense operate earning interest expense net net foreign exchange loss income net earning income tax expense income tax expense net earning share datum basic earning share dilute earning share cash dividend declare common share na weightedaverage basic share outstanding b weightedaverage dilute share outstanding b january cash dividend share common stock declare preseparation earning record reduction additional paidin capital refer note additional information cash dividend declare b january abbott laboratories distribute million share abbvie common stock period prior separation weightedaverage basic dilute share outstanding base number share abbvie common stock outstanding distribution date refer note information calculation basic diluted earning common share year end december accompany note integral consolidated financial statement abbvie inc subsidiary consolidate statement comprehensive income year end december million net earning foreign currency translation adjustment net tax benefit expense pension postemployment benefit net tax benefit expense unrealize loss gain marketable equity security net tax expense benefit hedging activity net tax expense benefit comprehensive loss income comprehensive income accompany note integral consolidated financial statement abbvie inc subsidiary consolidate balance sheet december millions share datum asset current asset cash equivalent shortterm investment account receivables net inventory net income tax receivable defer income taxis prepaid expense total current asset investment property equipment net intangible asset net amortization goodwill asset total asset liabilitie equity current liability shortterm borrowing current portion longterm debt lease obligation account payable accrue liability total current liability longterm liabilities longterm debt lease obligation commitment contingency stockholder equity common stock par value authorize share issue share december respectively common stock hold treasury cost share december respectively additional paidincapital retain earning accumulate comprehensive loss total stockholder equity total liability equity accompany note integral consolidated financial statement abbvie inc subsidiary consolidate statement equity accumulate common additional net parent year end december share common treasury paidin comprehensive retain company million outstanding stock stock capital loss earning investment total balance december net earning net transaction abbott laboratories assumption accumulate unrealized loss pension post employment benefit net tax benefit comprehensive loss net tax balance december separationrelate adjustment reclassification parent company net investment connection separation issuance common stock separation net earning comprehensive income net tax dividend declare share repurchase stockbase compensation plan balance december net earning comprehensive loss net tax dividend declare share repurchase stockbase compensation plan balance december accompanying note integral consolidated financial statement abbvie inc subsidiary consolidate statement cash flow year end december million bracket denote cash outflow cash flow operating activity net earning adjustment reconcile net earning net cash operating activity depreciation amortization intangible asset stockbase compensation upfront cost relate collaboration acquire inprocess research development net change operate asset liability net acquisition account receivables inventory prepaid expense asset account payable liability cash flow operating activity cash flow invest activity acquisition investment net cash acquire acquisition property equipment purchase investment security sale maturity investment security cash flow invest activity cash flow financing activity net change shortterm borrowing dividend pay purchase treasury stock proceed exercise stock option proceed issuance longterm debt net transaction abbott laboratory exclude noncash item net cash flow financing activity effect exchange rate change cash equivalent net decrease increase cash equivalent cash equivalent begin year cash equivalent end year supplemental information interest pay net portion capitalize income taxis pay cash flow operating activity include impact transaction financingrelated cost incur connection terminate propose combination shire refer note additional information accompany note integral consolidated financial statement abbvie inc subsidiary note consolidated financial statement note background basis presentation background principal business abbvie inc abbvie company discovery development manufacture sale broad line pharmaceutical product abbvie product generally sell worldwide directly wholesaler distributor government agency health care facility specialty pharmacy independent retailer abbvieowne distribution center public warehouse substantially abbvie sale united states wholesaler outside united states product sell primarily customer distributor depend market serve abbvie incorporate delaware april january abbvie independent publiclytraded company result distribution abbott laboratories abbott percent outstanding common stock abbvie abbott shareholder separation january abbott shareholder record close business december receive share abbvie common stock share abbott common stock hold record date abbvie common stock begin trade regularway ticker symbol abbv new york stock exchange january year end separationrelate adjustment total billion record stockholder equity separationrelate adjustment additional paidin capital principally reflect dividend abbvie shareholder declare preseparation earning quarter transfer certain pension plan liabilitie asset abbott abbvie legal split plan addition historical financial statement derive abbott record separationrelate adjustment include adjustment accumulate comprehensive loss reflect appropriate opening balance associate currency translation adjustment relate abbvie legal entity separation date refer note information separation pension plan connection separation abbvie abbott enter transition service agreement cover certain corporate support office service abbvie historically receive abbott service include information technology account payable payroll receivables collection treasury financial function order entry warehousing engineering support quality assurance support administrative service agreement facilitate separation allow abbvie operate independently prior establish standalone office function organization transition service provide month option oneyear extension majority transaction service agreement expire extension december year end december abbvie incur million million million respectively separationrelate expense include legal information technology regulatory fee principally classified sell general administrative expense sga consolidated statement earning basis historical presentation certain portion abbvie operation legal transfer abbvie asset net liability occur separation abbvie january time require transfer marketing authorization satisfy regulatory requirement certain country term separation agreement abbott abbvie responsible business activity conduct abbott behalf subject risk entitle benefit generate operation asset result related asset liability result operation report abbvie consolidated financial statement year end december net sale relate operation year end december total approximately million million respectively december asset liability consist primarily account receivable million inventory million asset million account payable accrue liability million december asset liability consist primarily account receivable million inventory million asset million account payable accrue liability million majority operation expect transfer abbvie end prior separation january historical financial statement abbvie prepare standalone basis derive abbott consolidated financial statement accounting record researchbase pharmaceutical business abbott abbvie period present accordingly abbvie financial statement period prior january present combine basis reflect abbvie financial position result operation cash flow business operate abbott prior separation conformity generally accept accounting principle gaap historical combine financial statement include allocation certain asset liability historically hold abbott corporate level specifically identifiable allocable abbvie prior cash equivalent shortterm investment restrict fund hold abbott allocate abbvie asset hold entity transfer abbvie december abbvie combine balance sheet reflect direct holding abbvie legal entity prior november longterm debt shortterm borrowing allocate abbvie debt record abbott directly attributable guarantee abbvie november abbvie issue billion longterm debt maturity range year billion commercial paper reflect abbvie combine balance sheet december abbvie intracompany transaction account eliminate prior intercompany transaction abbvie abbott consider effectively settle historical combine financial statement time transaction record result total net effect settlement intercompany transaction reflect combined statement cash flow year end december financing activity combine balance sheet december net parent company investment abbvie december outstanding transactions abbvie abbott reflect combined balance sheet outside net parent company investment abbvie inc december aggregate abbott total million million respectively primarily classify account receivables net abbvie consolidated balance sheet aggregate abbott total million million december respectively classify account payable accrue liabilities abbvie consolidated balance sheet prior separation january abbott provide abbvie certain service include administration treasury payroll employee compensation benefit travel meeting service public investor relation real estate service internal audit telecommunication information technology corporate income tax select legal service service continue provide abbvie temporary basis separation pursuant certain transition service agreement abbvie historical combine financial statement period prior january reflect allocation expense relate service expense allocate abbvie base direct usage benefit identifiable remainder allocate pro rata basis revenue headcount square footage number transaction measure abbvie consider expense allocation methodology result reasonable allocation indicative actual expense incur abbvie operate independent publiclytraded company period prior january allocation total million year end december prior separation january abbvie employee participate benefit stockbase compensation program maintain abbott portion cost program include abbvie historical combine financial statement note note description account postemployment benefit stockbase compensation respectively note summary significant accounting policy use estimate financial statement prepare accordance gaap necessarily include amount base estimate assumption management actual result differ amount significant estimate include amount sale rebate pension postemployment benefit income taxis litigation valuation intangible asset goodwill financial instrument inventory account receivable exposure basis consolidation consolidate financial statement year end december include account abbvie subsidiary control interest maintain control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity abbvie determine primary beneficiary investment company abbvie significant influence control interest account equity method abbvie share earning loss report income net investment generally account cost method intercompany balance transaction eliminate certain reclassification conform prior period consolidated financial statement current period presentation revenue recognition abbvie recognize revenue persuasive evidence arrangement exist delivery occur sale price fix determinable collectability sale price reasonably assure revenue product sale recognize title risk loss pass customer provision discount rebate sale incentive customer return adjustment provide period relate sale record sale incentive customer material historical datum readily available reliable estimating reduction gross sale revenue launch new product improve version exist product shipment excess customer normal requirement record condition note meet situation management record return reserve revenue necessary sale product right marketable product record revenue disposition right research development cost internal research development rd cost expense incur clinical trial cost incur party expense contract work perform contingent milestone payment party research development collaboration precommercialization milestone milestone payment obligation expense milestone result achieve payment party subsequent regulatory approval capitalize amortize remain useful life relate product amount capitalize payment include intangible asset net accumulate amortization collaboration arrangement company enter collaborative agreement party develop commercialize drug candidate collaborative activity include joint research development commercialization new product abbvie generally receive certain licensing right arrangement collaboration require upfront payment include additional milestone research development cost share royalty profit share payment contingent occurrence certain future event link success asset development commercialization upfront payment associate collaborative arrangement development stage expense acquire inprocess research development iprd subsequent payment partner achievement milestone development stage expense rd milestone achieve milestone payment partner subsequent regulatory approval capitalize intangible asset amortize cost product sell estimated useful life relate asset royalty expense cost product sell incurred advertising cost associate advertising expense incur include sga abbvie consolidated statement earning advertising expense million million million respectively pension postemployment benefit abbvie record annual expense relate define benefit pension postemployment plan base calculation include actuarial assumption include discount rate assume asset rate return compensation increase turnover rate health care cost trend rate abbvie review actuarial assumption annual basis make modification assumption base current rate trend actuarial loss gain amortize remain service attribution period employee corridor method accordance rule account postemployment benefit difference expect longterm return plan asset actual annual return amortize net period benefit cost fiveyear period prior separation abbvie employee participate certain define benefit pension postemployment plan sponsor abbott include participant abbott business plan account multiemployer plan abbvie historical combine financial statement year end december result asset liability record abbvie historical combine balance sheet recognize fund status plan subsequent separation abbott abbvie portion define benefit pension plan separate abbott define benefit pension plan december measurement date result fund status plan reflect abbvie consolidated balance sheet december abbvie sole sponsor certain define benefit pension postemployment plan fund status plan record abbvie combine balance sheet december consolidated balance sheet december refer note information abbvie pension postemployment plan income taxis income taxis account asset liability method provision federal state foreign income taxis calculate report pretax earning base current tax law defer taxis provide enact tax rate future tax consequence temporary difference difference financial statement carry asset liability respective tax basis tax benefit carryforward valuation allowance establish maintain base currently available information likely portion defer tax asset realize abbvie financial statement period prior income tax expense tax balance calculate abbvie separate taxpayer abbvie operation historically include tax return file abbott separation abbvie income tax expense income tax balance represent abbvie federal state foreign income taxis independent company result effective tax rate income tax balance necessarily comparable period prior separation cash equivalent cash equivalent include time deposit money market fund treasury security original maturity time purchase month investment shortterm investment consist primarily time deposit heldtomaturity debt investment marketable equity security classify availableforsale record fair value unrealize holding gain loss net tax include accumulate comprehensive loss abbvie consolidated balance sheet investment equity security trade public stock exchange heldtomaturity debt security record cost abbvie review carry value investment quarter determine temporary decline fair value exist abbvie consider factor affect investee factor affect industry investee operate general equity market trend company consider length time investment fair value cost nearterm prospect recovery abbvie determine temporary decline occur cost basis investment write charge income net availableforsale security unrealized loss recognize charge income remove accumulate comprehensive loss aoci account receivable account receivable state net realizable value allowance gross account receivable reflect good estimate probable loss inherent receivables portfolio determine basis historical experience specific allowance know troubled account currently available information account receivable write reasonable mean collect include litigation appropriate exhausted allowance million december million december inventory inventory value low cost firstin firstout basis market cost include material conversion cost inventory net consist follow december million finish good workinprocess material inventory net property equipment december million land building equipment construction progress property equipment gross accumulate depreciation property equipment net depreciation property equipment record straightline basis estimate useful life asset estimate useful life building range year year equipment leasehold improvement amortize life relate facility lease include renewal period appropriate asset whichever short depreciation expense year end december million million million respectively equipment include certain computer software software development cost incur connection develop obtain software internal use amortize year asset capital lease include property equipment consolidate balance sheet material litigation loss contingency provision record probable loss probable liability incur liability reasonably estimate base exist information good estimate minimum loss contingency probable range record legal fee expense incur product liability abbvie accrue product liability claim undiscounte basis probable liability incur liability reasonably estimate base exist information liability adjust quarterly additional information available receivables insurance recovery product liability claim record asset undiscounte basis probable recovery realize business combination result operation acquire company include abbvie result operation begin respective acquisition date asset acquire liability assume recognize date acquisition respective fair value excess fair value consideration transfer estimate fair value net asset acquire recognize goodwill contingent consideration recognize estimate fair value acquisition date determine utilize probability weight discount cash flow model subsequent change fair value contingent payment recognize income net consolidated statement earning fair value asset acquire liability assume certain case subject revision base final determination fair value legal cost diligence cost business valuation cost business acquisition cost expense incur goodwill intangible asset intangible asset acquire business combination record fair value discount cash flow model discount cash flow model require assumption time future net cash flow risk cost capital terminal value market participant definitelive intangible amortize estimate useful life abbvie review recoverability definitelive intangible asset event change circumstance indicate carry value asset recoverable abbvie compare project undiscounted cash flow generate asset carrying value undiscounte cash flow intangible asset carrying value intangible asset intangible asset write fair value usually discount cash flow loss record equal excess asset net carrying value fair value cash flow identify individual asset review apply low level cash flow largely independent cash flow asset liability goodwill indefinitelive asset amortize subject impairment review annually frequently indicator impairment exist impairment goodwill occur carry reporting unit exceed fair value reporting unit indefinitelive intangible asset consist capitalize iprd occur fair value iprd intangible asset carrying company test goodwill impairment assess qualitative factor determine likely fair value carrying company conclude likely fair value report unit carrying quantitative impairment test perform abbvie test indefinitelive intangible asset quantitative impairment test quantitative impairment test company use estimate future cash flow approach require significant judgment respect future volume revenue expense growth rate change work capital use foreign currency exchange rate selection appropriate discount rate asset grouping assumption estimate estimate assumption consistent company business plan market participant view company similar company use alternative estimate assumption increase decrease estimate fair value asset potentially result different impact company result operation actual result differ company estimate base company recent annual impairment test perform quarter company conclude goodwill impaired abbvie record impairment charge million relate certain onmarket product right japan increase generic competition charge include cost product sell abbvie record impairment charge million certain project development charge include rd expense impairment charge record acquire inprocess research development initial cost right iprd project acquire asset acquisition expense iprd project alternative future use cost include initial payment incur prior regulatory approval connection research development collaboration agreement provide right develop manufacture market andor sell pharmaceutical product fair value iprd project acquire business combination capitalize account indefinitelive intangible asset underlie project receive regulatory approval point intangible asset account definitelive intangible asset discontinuation point intangible asset write development cost incur acquisition expense incur indefinite definitelive asset subject impairment review discuss previously foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar period end exchange rate dollar effect arise translate net asset subsidiary change rate recognize comprehensive loss income net asset subsidiary highly inflationary economy remeasure functional currency report currency remeasurement recognize earning immaterial year present derivative derivative instrument recognize asset liability fair value abbvie balance sheet classify current longterm base schedule maturity instrument accounting change fair value derivative instrument depend formally designate qualify hedge relationship applicable accounting standard type hedging relationship derivative formally designate hedge company assess inception quarterly hedge derivative highly effective offset change fair value cash flow hedge item change fair value derivative designate fair value hedge hedge item attributable hedge risk recognize earning immediately fair value hedge hedge interest rate risk associate certain company fixedrate debt effective portion change fair value derivative designate cash flow hedge report accumulate comprehensive loss subsequently recognize earning consistent underlying hedged item cash flow hedge manage exposure change foreign currency exchange rate derivative designate qualify hedge adjust fair value current earning determine derivative long highly effective hedge company discontinue hedge account prospectively gain loss immediately reclassify accumulated comprehensive loss earning relate hedge forecast transaction long probable occur gain loss relate termination effective cash flow hedge forecast transaction probable occur defer recognize consistent income loss recognition underlie hedged item termination fair value hedge result fair value adjustment hedge item date termination new basis accrete par value date maturity derivative include designate hedge principally classified operating section consolidate statement cash flow consistent underlying hedged item refer note information abbvie derivative hedging activity recent accounting pronouncement financial accounting standard board issue accounting standard update asu summary amendment create revenue contract customer topic asset defer costscontract customer subtopic amendment asu supersede current revenue recognition requirement core principal new guidance entity recognize revenue depict transfer promise good service customer reflect consideration entity expect entitled exchange good service guidance effective annual reporting period begin december include interim period reporting period early application permit abbvie apply amendment follow method retrospectively prior reporting period present ii retrospectively cumulative effect initially apply amendment recognize date initial application abbvie currently assess impact adopt guidance consolidated financial statement note supplemental financial information interest expense net year end december million interest expense interest dividend income interest expense net interest expense net include million financing relate fee incur connection terminate propose combination shire income net income net include income resolution certain contractual agreement fair value adjustment contingent consideration impairment equity security income net primarily consist income million resolution contractual agreement account payable accrue liability december million sale rebate account payable abbott laboratory dividend payable salary wage commission royalty license arrangement account payable accrue liability longterm liability december millions defer income taxis pension postemployment benefit longterm liability note termination propose combination shire october abbvie board director withdraw previous recommendation abbvie stockholder favor propose combination shire plc company incorporate jersey shire recommend stockholder vote propose combination october abbvie shire mutually agree terminate propose combination yearende december company incur transaction financingrelate cost total billion billion record sga expense million record interest expense include sga expense break fee billion tax deductible pay abbvie shire october result termination propose combination addition company record million net foreign exchange loss primarily undesignated forward contract enter hedge anticipate foreign currency cash outflow associate terminate propose combination shire exit certain foreign currency position forward contract settle abbvie expect record additional foreign exchange loss million quarter reflect complete liquidation remain foreign currency position refer note information forward contract note information certain credit facility enter anticipation propose combination shire note earning share period subsequent separation abbvie calculate basic earning share ep pursuant twoclass method twoclass method earning allocation formula determine earning share common stock participate security accord dividend declare participation right undistribute earning method earning distribute undistributed allocate common share participate security base respective right receive dividend addition participate security include certain performancebase award exclude calculation ep treasurystock method abbvie forfeitable restrict stock unit rsus restrict stock award rsas include performancebase award participate dividend basis common share dividend nonforfeitable holder declare result forfeitable rsus rsas meet definition participate security dilutive effect participate security calculate dilutive treasury stock twoclass method year end december twoclass method dilutive dilutive effect outstanding rsus rsas year end december approximately million million respectively exclude denominator calculation dilute eps award include calculation eps treasury stock method additionally earning distribute undistribute allocable participate security include performancebase award include calculation ep treasurystock method exclude numerator calculation basic diluted earning share twoclass method earning allocable participate security year end december approximately million million respectively year end december approximately million million common share issuable stockbase compensation plan exclude computation earning common share assume dilution effect antidilutive period prior separation numerator basic diluted eps net earning attributable abbvie denominator basic dilute eps calculate million abbvie common share outstanding immediately follow separation number share calculate basic diluted earning share abbvie equity award outstanding prior separation note acquisition collaboration arrangement cash outflow relate collaboration acquisition product right arrangement total million million million respectively abbvie record iprd charge million million million respectively abbvie record expense million relate collaboration significant arrangement impact require contingent milestone payment summarize addition significant arrangement describe abbvie enter arrangement result charge iprd million million achievement certain development regulatory commercial milestone additional payment million million relate arrangement enter respectively possible predict reasonable certainty milestone achieve time achievement significant arrangement impact require contingent milestone payment include follow calico life sciences llc september abbvie calico life sciences llc calico enter novel rd collaboration agreement discover develop commercialize new therapy patient agerelate disease include neurodegeneration cancer abbvie record million expense consolidated statement operation relate commitment agreement million pay million pay early calico responsible research early development year continue advance collaboration project phase year period abbvie option exclusively license collaboration compound completion phase abbvie support calico early rd effort option exercise responsible latestage development commercial activity collaboration cost profit share equally company post option exercise infinity pharmaceuticals inc september abbvie enter global collaboration agreement infinity pharmaceuticals inc infinity develop commercialize duvelisib ipi treatment patient cancer agreement abbvie initial upfront payment million expensed iprd quarter achievement certain development regulatory commercial milestone abbvie additional payment million united states company jointly commercialize duvelisib share equally potential profit outside united states abbvie responsible commercialization duvelisib infinity eligible receive tiere doubledigit royalty net product sale ablynx nv september abbvie enter global collaboration agreement ablynx nv develop commercialize antiilr nanobody alx treatment inflammatory disease include rheumatoid arthritis systemic lupus erythematosus result charge iprd million achievement certain development regulatory commercial milestone abbvie additional payment million royalty net sale galapagos nv september abbvie record charge iprd million result enter global collaboration galapagos nv galapagos discover develop commercialize cystic fibrosis therapy achievement certain development regulatory commercial milestone abbvie additional payment million royalty net sale february abbvie record charge iprd million result enter global collaboration galapago develop commercialize nextgeneration oral janus kinase jak inhibitor phase development potential treat multiple autoimmune disease additional payment approximately billion require achievement certain development regulatory commercial milestone agreement alvine pharmaceuticals inc abbvie enter global collaboration alvine pharmaceuticals inc develop alv novel oral treatment patient celiac disease agreement abbvie initial upfront payment million expensed iprd second quarter abbvie additional payment total million pursuant arrangement action pharma abbvie record charge iprd million result acquisition abt previously refer ap drug development prevention acute kidney injury associate major cardiac surgery patient increase risk note goodwill intangible asset goodwill carry goodwill billion billion december respectively change goodwill balance primarily foreign currency translation change goodwill balance attributable foreign currency translation goodwill addition million relate product right acquire second quarter december accumulate goodwill impairment loss future impairment test goodwill perform annually quarter early indicator impairment exist intangible asset net follow table summarize abbvie intangible asset december december gross net gross net carry accumulate carrying carry accumulate carry million amortization amortization definitelive intangible asset develop product right license agreement total definitelive intangible asset indefinitelive research development total intangible asset intangible asset finite useful life amortize estimate useful life range year average year year develop product right license agreement respectively addition primarily relate acquisition million amortizable intangible asset license agreement onmarket product right united states average amortization period year amortization expense million million million respectively include cost product sell consolidated statement earning december anticipate annual amortization expense intangible asset record december million million million million million quarter impairment charge million record related certain onmarket product right japan increase generic competition charge base discount cash flow analysis include cost product sell indefinitelive intangible asset december relate iprd acquire business combination abbvie record impairment charge million certain project development charge base discount cash flow analysis include rd expense material impairment charge record related indefinitelive intangible asset note restructure plan prior year abbvie management approve plan realign worldwide manufacturing operation select domestic international commercial rd operation order reduce cost conjunction loss expect loss exclusivity certain product restructure charge record million primarily record cost product sell consolidated statement earning remainder record sga include charge cash cost million primarily relate employee severance contractual obligation abbvie management approve plan restructure certain commercial operation conjunction loss expect loss exclusivity certain product restructure charge record million primarily record sga cost product sell consolidated statement earning remainder record rd include charge cash cost million mainly relate employee severance contractual obligation abbvie management approve plan realign worldwide manufacturing operation select domestic international commercial rd operation order reduce cost abbvie incur restructuring charge approximately million employee severance contractual obligation primarily relate exit rd facility million record rd million sga expense consolidate statement earning follow summarize cash activity restructure reserve year end december millions accrue balance december restructuring charge payment adjustment accrue balance december restructuring charge payment adjustment accrue balance december restructuring charge payment adjustment accrue balance december payment adjustment include million reversal previously record restructuring reserve company reevaluation prior year decision exit manufacturing facility abbvie record additional restructuring charge million primarily accelerate depreciation note debt credit facility commitment contingency follow summary longterm debt december effective effective interest rate interest rate millions float rate note note note note note note fair value hedge unamortized bond discount total longterm debt lease obligation current portion noncurrent portion exclude effect related interest rate swap november abbvie issue billion aggregate principal senior note approximately billion senior note issue abbott partial consideration transfer asset abbott abbvie abbvie net proceed sale senior note senior note issue abbott finance payment november billion distribution abbott provide term separation agreement debt guarantee abbott abbvie separate abbott january abbvie redeem senior note series float note time senior note series float note time time redemption price equal principal senior note redeem plus makewhole premium abbvie redeem float note prior maturity december company compliance senior note covenant shortterm borrowing december shortterm borrowing include million million respectively commercial paper borrowing weightedaverage interest rate shortterm borrowing respectively prior october abbvie billion unsecured fiveyear revolve credit facility agreement october abbvie replace exist revolve credit facility billion fiveyear revolve credit facility support commercial paper borrowing december abbvie compliance financial covenant borrowing outstanding facility december december maturities longterm debt capital lease obligation follow table summarize abbvie future minimum lease payment noncancelable operating lease debt maturity future minimum lease payment capital lease obligation december operate debt maturity year end december million lease capital lease total obligation commitment fair value hedge unamortized bond discount na total debt lease obligation lease expense million million material separation abbvie enter agreement lease certain facility include office laboratory factory warehouse space principally noncancelable operating lease abbott abbvie operating lease generally include renewal option provide company pay taxis maintenance insurance operating cost lease property capital lease obligation relate automobile certain facility december annual future minimum lease payment capital lease obligation material debt maturity capital lease include million float note maturitie billion senior note contingency guarantee connection separation abbvie indemnify abbott liability result operation abbvie business income tax liability respect period prior distribution date liability agree abbvie abbott abbvie material exposure offbalance sheet arrangement specialpurpose entity activity include nonexchangetrade contract account fair value ordinary course business abbvie periodically enter thirdparty agreement assignment product right result abbvie secondarily liable obligation abbvie previously primarily liable base past experience likelihood payment agreement remote abbvie periodically acquire business product right abbvie agree pay contingent consideration base attain certain threshold base occurrence certain event note financial instrument fair value measure risk management policy company expose foreign currency exchange rate interest rate risk relate business operation company hedge policy attempt manage risk acceptable level base company judgment appropriate tradeoff risk opportunity cost company use derivative instrument reduce exposure foreign currency exchange rate company expose risk earning cash flow adversely impact fluctuation interest rate company periodically enter interest rate swap base judgment manage interest cost company agree exchange specify interval difference fix float interest amount calculate reference agreedupon notional derivative instrument trading purpose manage exposure change interest rate investment security company outstanding derivative instrument contain credit risk relate contingent feature collateral generally require financial instrument abbvie foreign subsidiary enter foreign currency forward exchange contract manage exposure change foreign exchange rate anticipate intercompany transaction denominate currency functional currency local entity contract notional amount total billion billion december december respectively designate cash flow hedge record fair value accumulate gain loss december include cost product sell time product sell generally exceed month company enter foreign currency forward exchange contract manage exposure foreign currency denominate trade payable receivables intercompany loan contract markedtomarket result gain loss reflect income generally offset loss gain foreign currency exposure manage december december abbvie hold notional amount billion billion respectively foreign currency forward exchange contract company enter undesignated forward contract total notional billion hedge anticipate foreign currency cash outflow associate terminate propose combination shire large portion contract original maturity quarter net settle fourth quarter company realize million net foreign exchange loss associate shirerelate forward contract abbvie party interest rate hedge contract designate fair value hedge total billion december december effect hedge change fixedrate interest obligation float rate portion debt abbvie record contract fair value adjust carrying fixedrate debt offset follow table summarize amount location abbvie derivative instrument december fair valuederivative liability fair valuederivative asset position position millions balance sheet caption balance sheet caption interest rate swap designate fair value hedge na longterm liability foreign currency forward exchange contract prepay expense account payable accrue hedging instrument liability prepaid expense account payable accrue designate hedge liability total certain derivative subject netting arrangement company counterpartie company offset derivative asset liability consolidated balance sheet follow table summarize activity derivative instrument amount location income expense gain loss reclassify net earning year end december respectively hedge ineffectiveness significant year end december gain loss recognize expense income loss gain comprehensive reclassify loss income income million income statement caption foreign currency forward exchange contract designate cash flow hedge cost product sell net foreign exchange loss designate hedge na na na gain interest rate swap designate fair value hedge na na na interest expense income net gainloss relate fair value hedge recognize net interest expense directly offset lossgain underlying hedged item fixedrate debt result net impact net interest expense year end december fair value measure fair value hierarchy accounting standard fair value measurement consist follow level level valuation base unadjusted quote price active market identical asset company ability access level valuation base quote price similar instrument active market quote price identical similar instrument market active modelbase valuation significant input observable market level valuation significant input unobservable market include use judgment company management assumption market participant use price asset liability follow table summarize basis measure certain asset liability carry fair value recur basis consolidated balance sheet december basis fair value measurement quote price active significant market significant balance identical observable unobservable december asset input input million level level level asset cash equivalent time deposit equity security foreign currency contract total asset liabilitie interest rate hedge foreign currency contract total liability follow table summarize basis measure certain asset liability carry fair value recur basis consolidated balance sheet december basis fair value measurement quote price active significant market significant balance identical observable unobservable december asset input input million level level level asset cash equivalent time deposit equity security foreign currency contract total asset liabilitie interest rate hedge foreign currency contract contingent consideration total liability fair value time deposit include cash equivalent shortterm investment determine base discount cash flow analysis reflect quote market rate similar instrument fair value time deposit approximate amortized cost short maturity instrument availableforsale equity security consist investment fair value determine publish market price unit multiply number unit hold consideration transaction cost derivative enter company value publicize spot curve interest rate hedge publicize forward curve foreign currency contract contingent consideration value discount cash flow technique reflect management expectation probability payment cumulative net unrealized holding gain availableforsale equity security total million million december december respectively transfer asset liability fair value measurement level follow table reconciliation fair value measurement use significant unobservable input level consist contingent payment relate acquisition investment million fair value december payment addition change fair value recognize earning fair value december payment change fair value recognize earning fair value december contingent payment primarily connection acquisition solvay pharmaceuticals business achievement certain sale milestone result payment approximately million million liability previously establish addition million relate acquisition product right change fair value recognize earning recognize net foreign exchange loss income net consolidated statement earning addition financial instrument company require recognize fair value consolidate balance sheet company certain financial instrument recognize historical cost basis fair value carry value fair value certain financial instrument december show table approximate book value fair value million asset investment liability shortterm borrowing current portion longterm debt lease obligation longterm debt lease obligation exclude fair value hedge follow table summarize basis measure approximate fair value financial instrument december basis fair value measurement quote price active significant market significant fair value identical observable unobservable december asset input input million level level level asset investment total asset liability shortterm borrowing current portion longterm debt lease obligation longterm debt lease obligation exclude fair value hedge total liability follow table summarize basis measure approximate fair value financial instrument december basis fair value measurement quote price active significant market significant fair value identical observable unobservable december asset input input million level level level asset investment total asset liability shortterm borrowing current portion longterm debt lease obligation longterm debt lease obligation exclude fair value hedge total liability investment consist cost method investment heldtomaturity debt security cost method investment include certain investment fair value determine publish market price unit multiply number unit hold consideration transaction cost determine fair value cost method investment company take consideration recent transaction financial information investee represent level basis fair value measurement fair value heldtomaturity debt security estimate base quote market price similar debt instrument fair value shortterm current borrowing approximate carry value short maturity instrument fair value longterm debt exclude fair value hedge determine publish market price debt instrument consideration transaction cost represent level basis fair value measurement counterpartie financial instrument consist select major international financial institution concentration risk company invest excess cash time deposit money market fund treasury security diversifie concentration cash different financial institution company monitor concentration credit risk associate deposit financial institution credit exposure limit establish limit concentration single issuer institution december abbvie approximately million net monetary asset denominate venezuelan bolivar convert rate vefusd venezuelan entity net sale million abbvie net monetary asset denominate venezuelan bolivar convert rate vefusd december resulted devaluation loss million company predict devaluation venezuelan currency use official rate continue support evolve fact circumstance circumstance change company conclude appropriate use different rate devaluation official rate occur result significant change abbvie result operation wholesaler account percent percent total net account receivable december december respectively substantially abbvie sale united states wholesaler addition net governmental receivables outstanding greece portugal italy spain total million december million december humira abbvie single large product account approximately percent percent percent abbvie total net sale respectively note postemployment benefit abbvie sponsor pension postemployment benefit plan include define benefit define contribution termination indemnity plan cover employee worldwide addition abbvie provide medical benefit primarily eligible retiree postretirement benefit plan net obligation plan reflect consolidated balance sheet december abbott sponsor plan prior separation abbvie employee participate certain international define benefit pension postemployment benefit opeb plan sponsor abbott plan include participant abbott business account multiemployer benefit plan abbvie combine financial statement year end december result asset liability record abbvie historical combine balance sheet december recognize fund status plan effective january connection separation abbvie abbott plans separate abbvie assume net benefit plan obligation previously provide abbott abbottsponsore define benefit postemployment benefit plan abbvie record expense million abbott voluntary contribution define benefit pension plan abbvie account multiemployer benefit plan total million abbvie sponsor plan prior separation abbvie employee participate abbott laboratories annuity retirement plan abbott principal domestic define benefit pension plan connection separation abbvie establish abbvie pension plan abbvie principal domestic define benefit pension plan substantially term abbott laboratories annuity retirement plan abbvie employee eligible participate abbott laboratories annuity retirement plan december automatically eligible abbvie pension plan quarter abbvie pension plan assume obligation relate asset employee abbott laboratories annuity retirement plan abbvie voluntary contribution million million respectively plan abbvie voluntary contribution million plan subsequent december benefit plan information table pertain global abbviesponsore define benefit pension postemployment plan define postemployment benefit plan plan year end december millions project benefit obligation begin period service cost interest cost employee contribution plan amendment assumption plan liabilitie removal plan actuarial gain loss benefit pay primarily foreign currency translation loss end period fair value plan asset begin period actual return plan asset company contribution employee contribution assumption plan asset benefit pay primarily foreign currency translation gain end period fund status december amount recognize consolidated balance sheet asset current liability longterm liability net liability december actuarial loss net prior service cost aoci december project benefit obligation pbo table include billion billion december respectively relate international define benefit pension plan number generally fund accordance local regulation benefit payment plan fund company asset fund status december reflect abbvie consider release new mortality table projection scale society actuary improvement estimate future mortality opt change new table plan reflect table accumulate benefit obligation abo billion billion december respectively plan reflect table abo exceed plan asset december abo pbo aggregate plan asset billion billion billion respectively amount recognize aoci oci define benefit pension postemployment plan actuarial gain loss prior service cost credit recognize net periodic benefit cost recognize netoftax basis aoci amortize net periodic benefit cost future follow summary pretax gain loss include oci year end december millions define benefit plan actuarial gain loss prior service cost amortization actuarial loss prior service cost foreign exchange loss total pretax gain loss recognize oci postemployment plan actuarial gain loss prior service cost amortization actuarial loss prior service cost total pretax gain loss recognize oci pretax actuarial gain loss prior service cost include aoci december expect recognize net periodic benefit cost million define benefit plan million postemployment plan net periodic benefit cost year end december millions define benefit plan service cost interest cost expect return plan asset amortization actuarial loss prior service cost net periodic pension benefit cost postemployment plan service cost interest cost amortization actuarial gain prior service cost net periodic opeb cost weightedaverage assumption determine benefit obligation measurement date define benefit plan discount rate rate compensation increase postemployment plans discount rate rate compensation increase assumption calculate december measurement date benefit obligation calculation net periodic benefit cost weightedaverage assumption determine net periodic benefit cost define benefit plan discount rate expect longterm rate return plan asset expect rate change compensation postemployment plan discount rate na purpose measure postretirement health care obligation measurement date company assume pre post annual rate increase capita cost cover health care benefit rate assume decrease gradually remain level purpose measure postretirement health care cost company assume pre post annual rate increase capita cost cover health care benefit rate assume decrease gradually remain level assume health care cost trend rate significant effect amount report health care plan december percentage point change assume health care cost trend rate follow effect percentage point year end december million increase decrease service cost interest cost project benefit obligation define benefit pension plan asset basis fair value measurement quote price significant significant balance active market observable unobservable december identical asset input input million level level level equitie large capa mid capb internationalc fix income security government securitiesd corporate debt instrumentse government security international absolute return fundsf real asset otherg fair value plan asset basis fair value measurement quote price significant significant balance active market observable unobservable december identical asset input input million level level level equitie large capa mid capb internationalc fix income security government securitiesd corporate debt instrumentse government security international absolute return fundsf real asset otherg fair value plan asset mix pool index fund actively manage equity account benchmarke large cap index b mix pool index fund actively manage equity account benchmarke mid cap index c mix pool index fund actively manage equity account benchmarke nonus equity index develop emerge market security hold actively manage account pool index fund mutual fund e security hold actively manage account pool index fund mutual fund f fund global mandate flexibility allocate capital broadly wide range asset class strategy include limited equity fix income commodity financial future currency security objective outperform agree benchmark specific return volatility target g investment cash cash equivalent equity value quote price value publish market price equitie common collective trust register investment company value significant observable input value net asset value nav provide fund administrator nav base value underlie asset own fund minus liability fix income security value significant observable input value price obtain independent financial service industryrecognize vendor absolute return fund commodity value nav provide fund administrator follow table summarize change value plan asset measure significant unobservable input level million balance january actual return plan asset hand year end assumption level asset purchase sale settlement net balance december investment mix equity security fix income asset allocation strategy base achieve desire return balance high return volatile equity security low return volatile fix income security investment allocation establish plan generally range market industry sector capitalization size case fix income security maturity credit quality target investment allocation abbvie pension plan equity security fix income security asset allocation strategy holding know significant concentration risk plan asset abbvie pension plan plan asset plan expect return asset show base management expectation longterm average rate return achieve underlie investment portfolio establish assumption management consider historical expect return asset class plan invest current economic capital market condition expect pension postemployment payment define postemployment million benefit plan plan table reflect total benefit payment expect pay participant include payment fund company asset pay plan prior separation abbvie employee participate abbott laboratories stock retirement plan abbott principal define contribution plan abbvie record expense million relate plan connection separation abbvie establish abbvie saving plan abbvie principal define contribution plan substantially term abbott laboratories stock retirement plan abbvie employee eligible participate abbott laboratories stock retirement plan december automatically eligible abbvie saving plan abbvie record expense million million relate plan abbvie provide certain postemployment benefit primarily salary continuation plan qualify employee accrue related cost service live employee note equity stockbased compensation stockbase compensation expense million million million respectively principally classify sga period present remainder classify rd cost product sell related tax benefit recognize million million million respectively stockbase compensation expense allocate abbvie base portion abbott incentive stock program abbvie employee participate compensation expense stockbase award measure base fair value award date stockbase award grant adjust estimate number award expect vest forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate compensation cost stockbase award amortize service period shorter vest period employee retirement eligible charge compensation expense stockbase award grant retirementeligible employee compensation expense recognize immediately grant date employee able retain award continue provide service prior separation abbvie employee participate abbott incentive stock program abbvie incentive stock program adopt time separation facilitate assumption certain award grant abbott incentive stock program authorize postseparation grant different form benefit include nonqualified stock option rsas rsus performancebase rsas rsus abbvie incentive stock program million share common stock reserve issuance respect postseparation award participant connection separation outstanding abbott employee stock option rsas rsus previously issue abbott incentive stock program adjust convert new abbott abbvie stockbase award formula design preserve intrinsic value fair value award immediately prior separation separation january holders abbott stock option rsas rsus generally receive abbvie stock base award abbott stockbased award outstanding adjust award retain vest schedule expiration date original award abbvie award grant abbott employee connection separation realize excess tax benefit associate stockbase compensation total million million respectively present consolidated statement cash flow outflow operating section inflow financing section stock option exercise price option grant equal percent market value date grant stock option typically contractual term year generally vest onethird increment threeyear period fair value stock option determine blackschole model weightedaverage grantdate fair value stock option grant respectively stockbase compensation expense attributable option year present material follow table summarize abbvie stock option activity abbvie abbott employees year end december weighted weight average average remain aggregate option thousand aggregate intrinsic value million option exercise price life year intrinsic value outstanding december grant exercise lapsed outstanding december exercisable december aggregate intrinsic value table represent difference exercise price company close stock price day trading year end december total intrinsic value option exercise million million respectively option issue abbott incentive stock program abbvie employee prior separation total intrinsic value option exercise million total fair value option vest million excess tax benefit realize option exercise total million december million unrecognized compensation cost relate stock option expect recognize expense approximately year rsas rsus rsas generally vest year rsas vest year onethird award vest year rsus vest year vest recipient receive share common stock vest rsu addition abbvie grant select executive key employee performancebase rsas rsus vest contingent meet companywide performance goal include abbvie achieve minimum return equity fair value rsas rsus include performancebase award determine base number share grant quote price common stock date grant abbvie assume performance goal achieve goal meet compensation cost recognize previously recognize compensation cost reverse follow table summarize abbvie rsa rsu activity include performancebase award abbvie abbott employees year end december weightedaverage share unit thousand share unit grant date fair value outstanding december grant vested lapsed outstanding december fair market value rsas rsus vest million million respectively rsas rsus issue abbott incentive stock program prior separation fair market value rsas rsus vest million weightedaverage grantdate fair value share rsas rsus grant amount adjust reflect separation abbott december million unrecognized compensation cost relate rsas rsus expect recognize expense approximately year cash dividend december board director declare quarterly cash dividend share common stock stockholder record january pay february additionally quarterly cash dividend declare board director february share represent increase percent previous quarterly rate share pay june september board director declare quarterly cash dividend share pay august november respectively additionally october board director declare increase company quarterly cash dividend share share common stock stockholder record january pay february stock repurchase program february abbvie board director authorize billion stock repurchase program october abbvie board director authorize new billion stock repurchase program effective immediately supersede previous authorization expect execute year stock repurchase authorization permit purchase abbvie share time time open market private transaction management discretion depend company cash flow net debt level market condition plan time limit discontinue time abbvie repurchase approximately million share million share million million respectively open market share repurchase program record acquisition cost include related expense available general corporate purpose abbvie remain share repurchase authorization billion december accumulate comprehensive loss follow table summarize change balance component aoci net tax year end december unrealize gain foreign pension loss currency post marketable translation employment equity hedging millions bracket denote loss adjustment benefit security activity total balance december comprehensive income reclassification amount reclassify accumulated comprehensive income net currentperiod comprehensive income separationrelate adjustment balance december comprehensive income reclassification amount reclassify accumulated comprehensive income net currentperiod comprehensive income separationrelate adjustment balance december comprehensive income reclassification amount reclassify accumulated comprehensive income net currentperiod comprehensive loss income balance december comprehensive loss include foreign currency translation adjustment total loss billion principally drive impact substantial weakening euro translation company eurodenominate asset ii weaken foreign currency combination increase concentration cash denominate foreign currency accumulate anticipation terminate propose combination shire plc table present significant amount reclassify component accumulate comprehensive loss year end december year end december million pension postemployee benefit amortization actuarial loss tax expense total reclassification net tax hedging activity gain loss designate cash flow hedge tax expense total reclassification net tax addition common stock abbvie authorize capital include million share prefer stock par value december share prefer stock issue outstanding note income taxis earning income taxis year end december million domestic foreign total earning income taxis increase domestic loss income taxis year end december drive transaction financingrelate cost associate terminate propose combination shire refer note information income taxis year end december million current domestic foreign total current taxis defer domestic foreign total defer taxis total income taxis effective tax rate reconciliation year end december statutory tax rate state taxis net federal benefit effect foreign operation tax credit brand prescription drug fee valuation allowance resolution uncertain tax position nondeductible litigation loss net effective tax rate effective tax rate fluctuate year year allocation company taxable earning jurisdiction certain discrete factor event year include acquisition collaboration effective tax rate differ statutory tax rate principally benefit foreign operation reflect impact low income tax rate location outside united states tax exemption incentive puerto rico foreign tax jurisdiction business development activity cost repatriation decision effective tax rate period reflects benefit tax credit principally relate research development credit orphan drug tax credit puerto rico excise tax credit research development credit legislation enact fourth quarter extend credit december increase effective tax rate principally drive additional expense million relate brand prescription drug fee non deductible state tax valuation allowance million discuss defer tax asset liability section follow july internal revenue service issue final rule regulation brand prescription drug fee annual nontaxdeductible fee payable federal government affordable care act base allocation company market share brand prescription drug sell certain government program prior year final rule accelerate expense recognition criterion fee obligation year fee pay year market share allocate fee determine change require abbvie industry participant recognize additional year expense effective income tax rate reflect income tax expense relate current earning outside united states deem indefinitely reinveste effective income tax rate include recognition tax benefit total approximately million result favorable resolution tax position pertain prior year puerto rico enact legislation assess excise tax begin certain product manufacture puerto rico tax levy gross inventory purchase entities puerto rico include cost product sell consolidated statement earning majority tax creditable income tax purpose defer tax asset liability december millions defer tax asset compensation employee benefit accrual reserve chargeback rebate defer revenue depreciation state income taxis net operating loss credit carryforward total defer tax asset valuation allowance total net defer tax asset defer tax liability excess book basis tax basis intangible asset repatriation foreign earning total defer tax liability net defer tax asset gross federal net operating loss carryforward december million available use gross state net operating loss tax credit carryforward december billion million respectively state tax carryforward expire period december foreign net operating loss carryforward million majority foreign loss carryforward expiration period december company valuation allowance million million respectively principally relate state net operating loss credit carryforward expect realize deferred income taxis provide approximately billion undistributed earning foreign subsidiary earning indefinitely reinveste continued use foreign operation complexity tax law assumption practicable estimate income taxis earning distribute unrecognized tax benefit year end december million balance january increase current year tax position increase prior year tax position decrease prior year tax position settlement lapse statute limitation separationrelate adjustment balance december abbvie abbott enter tax sharing agreement effective date separation provide abbott liable indemnify abbvie income tax liability period prior separation table reflect reduction billion relate tax period prior separation abbott primary obligor treasury regulation member consolidated group severally liable federal income tax liability member consolidated group accordingly respect periods abbvie include abbott consolidated group abbvie liable government federal income tax liability incur consolidated group extent discharge member liability impose abbvie entitle indemnify abbott pursuant tax sharing agreement abbvie responsible unrecognized tax benefit relate interest penalty period separation instance exist entity transfer abbvie separation result abbvie continue account tax uncertainty extent obligation relate period prior separation reimbursement receivable approximately million record asset december recognize net potential tax benefit impact company effective tax rate million million respectively company routinely audit tax authority significant jurisdiction number audits currently underway reasonably possible month uncertain tax position settle result decrease gross unrecognized tax benefit potential resolution federal state foreign examination expiration statute limitation company gross unrecognized tax benefit balance change month million significant federal state local international matter conclude year company believe adequate provision income tax uncertainty abbvie recognize accrue interest penalty relate uncertain tax position income tax expense amount expense liability accrue immaterial year end december uncertain tax position generally include longterm liability consolidated balance sheet note legal proceeding contingency subject certain exception specify separation agreement abbvie assume liability control pende threatened legal matter relate business include liability claim legal proceeding relate product business discontinue prior distribution assume retain liability indemnify abbott liability arise result assume legal matter abbvie involve claim legal proceeding investigation include describe record accrual balance litigation december significant year legal proceeding occur result change estimate loss accrue abbvie feasible predict outcome proceeding exposure certainty management believe ultimate disposition material adverse effect abbvie consolidated financial position cash flow result operation pende lawsuit file unimed pharmaceuticals inc solvay pharmaceuticals inc company abbott acquire february know abbvie product llc consolidated pretrial purpose united states district court northern district georgia multi district litigation rule androgel antitrust litigation mdl case bring private plaintiff federal trade commission ftc generally allege solvay patent litigation involve androgel sham litigation patent litigation settlement agreement relate agreement generic company violate federal state antitrust law state consumer protection unjust enrichment law plaintiff generally seek monetary damage andor injunctive relief attorney fee mdl include individual plaintiff lawsuit b seven purport class action c federal trade commission v watson pharmaceuticals inc et al file united states district court northern district georgia follow district court dismissal plaintiff claim appellate proceeding lead reinstatement claim patent litigation settlement proceeding discovery district court september federal trade commission ftc file suit united states district court eastern district pennsylvania abbvie allege patent litigation generic company androgel sham litigation patent litigation settlement generic company violate federal antitrust law ftc complaint seek monetary damage injunctive relief august putative class action lawsuit sidney hillman health center rochester et al v abbvie inc et al file abbvie united states district court northern district illinois healthcare benefit provider allege violation federal rico statutes state deceptive business practice unjust enrichment law connection reimbursement certain use depakote plaintiff seek monetary damage andor equitable relief attorney fee august district court dismiss plaintiff claim prejudice plaintiff appeal district court decision united states court appeal seventh circuit matter currently pende lawsuit file abbvie generally allege patent litigation settlement involve niaspan enter kos pharmaceuticals inc company acquire abbott laboratories presently subsidiary abbvie generic company violate federal state antitrust law state unfair deceptive trade practice unjust enrichment law plaintiff generally seek monetary damage andor injunctive relief attorney fee september pende putative class action lawsuit centralize consolidated coordinate pretrial proceeding united states district court eastern district pennsylvania multidistrict litigation rule niaspan antitrust litigation mdl november glaxosmithkline file lawsuit abbott laboratories united states district court northern district california allege abbott violate antitrust law connection norvir reprice march jury find abbott violate antitrust law breach license agreement plaintiff january judge panel united states court appeals ninth circuit reverse verdict remand case new trial alleged improper exclusion potential juror case return trial court proceeding abbvie assume liability control proceeding connection separation abbott abbvie seek enforce patent right relate testosterone gel drug abbvie sell trademark androgel case file united states district court district delaware february abbvie allege perrigo company perrigo israel pharmaceutical ltd propose generic product infringe abbvie patent seek declaratory injunctive relief second case file united states district court district delaware march abbvie allege watson laboratories inc actavis inc propose generic product infringe abbvie patent seek declaratory injunctive relief november abbvie watson actavis enter confidential settlement license agreement litigation dismiss stipulation party abbvie seek enforce patent right relate ritonavirlopinavir tablet drug abbvie sell trademark kaletra case file united states district court northern district illinois march abbvie allege matrix laboratories inc matrix laboratories ltd mylan inc propose generic product infringe abbvie patent seek declaratory injunctive relief matrix motion november court grant fiveyear stay litigation good cause lift stay show july stay lift pursuant original term court order enter abbvie seek enforce patent right relate ritonavir tablet drug abbvie sell trademark norvir case pende united states district court southern district ohio april abbvie allege roxane laboratories inc roxane propose generic product infringe abbvie patent seek declaratory injunctive relief case file united states district court southern district ohio july abbvie allege roxane propose generic ritonavir product infringe additional abbvie patent seek declaratory injunctive relief additional patent september abbvie roxane enter settlement license agreement date license confidential party enter stipulation dismiss ohio litigation separate case file united states district court district delaware abbvie allege hetero usa inc hetero labs limited propose generic ritonavir tablet product infringe abbvie patent seek declaratory injunctive relief november abbvie hetero enter confidential settlement license agreement litigation dismiss stipulation party separate case file united states district court district delaware july abbvie allege aurobindo pharma limited aurobindo pharma usa inc propose generic ritonavir tablet product infringe abbvie patent seek declaratory injunctive relief december abbvie aurobindo enter confidential settlement license agreement litigation dismiss stipulation party separate case file united states district court district delaware october abbvie allege mylan pharmaceutical inc proposed generic ritonavir tablet product infringe abbvie patent seek declaratory injunctive relief abbvie seek enforce certain patent right cover use fully human antitnf alpha antibody methotrexate treat rheumatoid arthritis case file united states district court district massachusetts abbvie allege centocor ortho biotech inc janssen biotech inc product simponi infringe abbvie patent seek damage injunctive relief december party enter settlement license agreement term confidential litigation dismiss prejudice november individual file putative class action lawsuit behalf purchaser seller certain shire plc securities june october abbvie chief executive officer united states district court northern district illinois allege defendant andor responsible material misstatement violation federal security law connection abbvie propose transaction shire complaint seek unspecified monetary damage injunctive relief november putative class action lawsuit medical mutual ohio v abbvie inc et al file manufacturer testosterone replacement therapie trt include abbvie united states district court northern district illinois behalf insurance company health benefit provider thirdparty payor pay trt include androgel claim assert include violation federal racketeer influence corrupt organization act state consumer fraud deceptive trade practice law complaint seek unspecified monetary injunctive relief december shareholder derivative lawsuit plumber steamfitter local pension plan v jp morgan securities llc et al file delaware chancery court allege abbvie director breach fiduciary duty connection shire transaction approval termination lawsuit seek unspecified compensatory damage abbvie relief note segment geographic area information abbvie operate business segmentpharmaceutical product substantially abbvie sale wholesaler outside united states product sell primarily health care provider distributor depend market serve worldwide net sale key product follow year end december millions humira androgel kaletra synagis lupron synthroid sevoflurane creon dyslipidemia product duodopa viekira net sale net sale external customer base country sell product follow year end december millions united states germany netherlands united kingdom france japan canada spain brazil italy country net sale longlive asset include net property equipment billion billion december billion billion respectively locate united states puerto rico million million respectively locate europe note quarterly financial datum unaudite million share datum quarter net sale gross margin net earning basic earning share dilute earning share cash dividend declare common share second quarter net sale gross margin net earning basic earning share dilute earning share cash dividend declare common share quarter net sale gross margin net earning basic earning share dilute earning share cash dividend declare common share fourth quarter net sale gross margin net loss earning b basic loss earning share c dilute loss earning share c cash dividend declare common share january cash dividend share common stock declare preseparation earning record reduction additional paidin capital refer note additional information cash dividend declare b result fourth quarter include transaction financingrelate cost incur connection terminate propose combination shire million aftertax charge relate research development collaboration agreement calico million aftertax charge result enter global collaboration infinity refer note information relate termination propose combination shire collaboration calico infinity respectively c basic loss share fourth quarter calculate treasurystock method dilutive approximately million common share exclude computation dilute loss share assume dilution effect antidilutive report independent register public accounting firm board director shareholders abbvie inc audit accompany consolidated balance sheet abbvie inc subsidiary december relate consolidated statement earning comprehensive income equity cash flow year end financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position abbvie inc subsidiary december consolidate result operation cash flow year end conformity generally accept accounting principle audit accordance standard public company accounting oversight board united states abbvie inc subsidiary internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework report date february express unqualified opinion thereon ernst young llp chicago illinois february report independent register public accounting firm board director shareholders abbvie inc audit accompany combined statement earning comprehensive income equity cash flow abbvie inc subsidiary company year end december combine financial statement responsibility company management responsibility express opinion financial statement base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance combine financial statement free material misstatement company require engage perform audit internal control financial reporting audit include consideration internal control financial reporting basis design audit procedure appropriate circumstance purpose express opinion effectiveness company internal control financial reporting accordingly express opinion audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audit provide reasonable basis opinion opinion combine financial statement present fairly material respect result operation cash flow company year end december conformity accounting principle generally accept united states america describe note accompany combine financial statement derive consolidated financial statement accounting record abbott laboratory combine financial statement include expense allocation certain corporate function historically provide abbott laboratory allocation reflective actual expense incur company operate separate entity apart abbott laboratories deloitte touche llp chicago illinois march item change disagreement accountant account financial disclosure item control procedure disclosure control procedure evaluation disclosure control procedure chief executive officer richard gonzalez chief financial officer william j chase evaluate effectiveness abbvie disclosure control procedure end period cover report conclude abbvie disclosure control procedure effective ensure information abbvie require disclose report file submit securities exchange commission securities exchange act record process summarize report time period specify commission rule form ensure information require disclose abbvie report file submit exchange act accumulate communicate abbvie management include principal executive officer principal financial officer appropriate allow timely decision require disclosure internal control financial reporting management annual report internal control financial reporting management report internal control financial reporting include hereof report abbvie independent register public accounting firm relate assessment effectiveness internal control financial reporting include hereof change internal control financial reporting separation abbott abbvie begin phase global implementation new enterprise resource planning system relate technology infrastructure transaction processing service replace information technology infrastructure transactional service provide abbvie abbott transition service agreement initiative expect complete include modification design operation control financial reporting abbvie review control design effectiveness prior implementation phase change abbvie internal control financial reporting define rule af exchange act materially affect reasonably likely materially affect abbvie internal control financial reporting quarter end december inherent limitation effectiveness control abbvie management include chief executive officer chief financial officer expect abbvie disclosure control internal control financial reporting prevent detect error fraud control system matter design operate provide reasonable absolute assurance control system objective meet design control system reflect fact resource constraint benefit control consider relative cost inherent limitation control system evaluation control provide absolute assurance misstatement error fraud occur control issue instance fraud detect inherent limitation include reality judgment decisionmake faulty breakdown occur simple error mistake control circumvent individual act person collusion people management override control design system control base certain assumption likelihood future event assurance design succeed achieve state goal potential future condition projection evaluation control effectiveness future period subject risk time control inadequate change condition deterioration degree compliance policy procedure item b information management report internal control financial reporting management abbvie responsible establish maintain adequate internal control financial reporting term define rule f securities exchange act abbvie internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle unite states internal control system matter design inherent limitation system determine effective provide reasonable assurance respect financial statement preparation report management assess effectiveness abbvie internal control financial reporting december make assessment management criterion set forth committee sponsor organization treadway commission coso internal controlintegrate framework framework base assessment management conclude abbvie maintain effective internal control financial reporting december base coso criterion effectiveness abbvie internal control financial reporting december audit ernst young llp independent register public accounting firm state attestation report appear hereof express unqualified opinion effectiveness abbvie internal control financial reporting december report independent register public accounting firm board director shareholders abbvie inc audit abbvie inc subsidiary internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission framework coso criteria abbvie inc subsidiary management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle company internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion abbvie inc subsidiary maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated balance sheet december relate consolidated statement earning comprehensive income equity cash flow year end report date february express unqualified opinion thereon ernst young llp chicago illinois february iii item director executive officer corporate governance incorporate reference information concern director nominee board director committeescommittee board director section beneficial ownership report compliance procedure recommendation nomination director transaction business annual meeting include abbvie inc proxy statement proxy statement file march incorporate reference text find caption executive officer registrant page hereof abbvie code business conduct require business activity conduct compliance law regulation ethical principle value director officer employee abbvie require read understand abide requirement code business conduct applicable abbvie code business conduct available corporate governance section abbvie investor relation website wwwabbvieinvestorcom waiver code business conduct director executive officer abbvie audit committee abbvie disclose amendment waiver provision code conduct principal executive officer principal financial officer principal accounting officer controller person perform similar function website business day follow date amendment waiver addition abbvie disclose waiver code business conduct executive officer director website abbvie chief ethic compliance officer report chief executive officer public policy committee chief ethic compliance officer responsible overseeing administer monitor abbvie compliance program item executive compensation material include proxy statement heading director compensation executive compensation compensation committee report incorporate reference proxy statement file march item security ownership certain beneficial owner management relate stockholder matter equity compensation plan information follow table present information december abbvie equity compensation plan abbvie common stock authorize issuance c number security remaining number b available security weight future issuance issue average exercise equity exercise price compensation outstanding outstanding plan exclude option option security warrant warrant reflect plan category right right column equity compensation plan approve security holder equity compensation plan approve security holder total include share issuable abbvie incentive stock program pursuant award grant abbott adjust abbvie award connection abbvie separation abbott weightedaverage exercise price include outstanding restricted stock unit restrict stock award exercise price b information concern security ownership incorporate reference material head security ownershipsecuritie ownership executive officer director proxy statement proxy statement file march item certain relationship relate transaction director independence material include proxy statement heading board director committee corporate governance material procedure approval related person transaction incorporate reference proxy statement file march item principal accounting fee service material include proxy statement heading audit fee nonaudit fee policy audit committee preapproval audit permissible nonaudit services independent register public accounting firm incorporate reference proxy statement file march iv item